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RESUMO 
Desde a descoberta dos primeiros antibióticos em meados do seculo XX, que estes têm 
vindo a ser utilizados, frequentemente, de forma indiscriminada para combater infeções 
bacterianas, o que tem sido associado a um aumento do número de infeções causadas por 
bactérias multirresistentes (MDRs). Apesar de várias medidas terem sido já implementadas para 
evitar a incidência de microrganismos multirresistentes, estas têm-se mostrado ineficazes, 
ficando a comunidade científica responsável por encontrar novas formas de combater os 
mecanismos de resistência bacterianos. 
Um dos mecanismos recentemente descritos envolve a actuação de proteínas 
denominadas lipocalinas bacterianas (BCNs, anteriormente conhecidas por YceI). Inicialmente 
descritas em Burkholderia cenocepacia K56-2, estas proteínas são secretadas pelas bactérias 
capturando antibióticos hidrofóbicos no meio extracelular, impedindo o antibiótico de atuar sobre 
a bactéria, aumentando assim a concentração mínima inibitória (CIM) do respetivo antibiótico. 
Este mecanismo não aparente ser restrito às bactérias produtoras de BCNs, exercendo 
actividade e proteção sobre a comunidade bacteriana envolvente. 
As BCNs consistem em proteínas de baixa massa molecular, altamente conservadas 
entre as bactérias, apresentando uma conformação característica tridimensional (3D) de barril-
β, seguida por uma hélice-α. Geralmente secretadas para o meio periplasmático, livres ou 
ancoradas à membrana plasmática, estas proteinas podem ainda surgir no meio extracelular ou, 
ainda, no citosol da bactéria. As BCNs descritas até à data ainda se encontram muito pouco 
caracterizadas funcionalmente, desconhecendo-se a capacidade de ligação de proteínas 
ortologas das descritas originalmente em alguns organismos aos antibioticos. Desta forma, esta 
tese focou-se no estudo do homólogo de BCN em Klebsiella pneumoniae kp52.145 designado 
BcnK. Esta bactéria Gram-negativa, pertencente à família das Enterobacteriaceae, é um 
importante agente patogénico responsável por surtos de pneumonia, entres outras infeções, em 
ambientes hospitalares e na comunidade. Tal como se verifica com outros agentes patogénicos, 
o número de estirpes de K. pneumoniae multirresistentes tem vindo a aumentar. Os principais 
mecanismos de resistência presentes nas estirpes clínicas desta espécie consistem em: (i) 
produção de β-lactamases de largo espectro de atuação, capazes de hidrolisar cefalosporinas e 
antibióticos do grupo dos monobactâmicos, ou (ii) produção de carbapenemases, que possuem 
a capacidade de hidrolisar um largo espectro de antibióticos, incluindo carbapenemes. Estes 
genes possuem a capacidade de se propagar horizontalmente entre estirpes da mesma ou outras 
espécies, tendo sido detetadas em várias regiões do mundo, constituindo assim uma ameaça 
para a saúde pública. 
 Assim, a fim de se caracterizar funcionalmente a proteína BcnK, o gene correspondente 
(bcnK) foi expresso por clonagem em Escherichia coli no vetor pDA-CTHis, contendo uma cauda 
de seis histidinas na extremidade C-terminal, dando origem a pDG1. A proteína recombinante 
expressa foi purificada com sucesso por cromatografia de afinidade. A verificação da expressão 
desta proteína foi efectuada através de SDS-PAGE e Western-blot. Apesar de se ter verificado 
que a expressão de BcnK conferiu um aumento da CMI, traduzido por uma diferença de 
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crescimento de cerca de 65.5% OD600 a uma concentração de 1.0 µg/mL de polimixina B, em 
testes de proteção com Pseudomonas aeruginosa PAO1, não foi possível repetir este ensaio 
devido à agregação da proteína observada durante a diálise em tampão PBS, o que 
impossibilitou a quantificação da proteína e a sua utilização em ensaios subsequentes. Especula-
se que a agregação observada se deveu, possivelmente, à componente lipídica N-acil-S-sn-1,2-
diacilcerilcisteína presente na exterminade N-terminal de BcnK. Desta forma, procedeu-se a nova 
tentativa de clonagem de bcnK no mesmo vetor, removendo-se a sequência do péptido sinal. 
Contudo, não se obtiveram quantidades suficientes da proteína produzida  para se proceder à 
sua purificação. Assim, alternativamente, clonou-se bcnK no vetor induzível por IPTG, pET-28a 
(+), contendo caudas de histidina nas extremidades N- e C- terminal (pDG7) e, em paralelo, 
clonou-se no mesmo vetor, usando apenas uma cauda de histidinas na extremidade N-terminal 
(pDG8). A expressão do gene bcnK nestes vetores levou à produção de quantidades suficientes 
de proteína para purificação. No entanto, a expressão da construção genética em pDG7 conduziu 
a elevados níveis de agregação da proteína durante a diálise, possivelmente devido à presença 
das caudas de histidina. Contrariamente ao esperado, a expressão de BcnK em pDG8 não 
conduziu ao aumento da CMI nos ensaios de proteção. Desta forma, admitiu-se a hipótese de 
que a proteína recombinante produzida sem péptido sinal teria uma conformação incorreta para 
o exercício da sua função biológica ou de que a cauda de histidinas presente na extremidade N-
terminal pudesse gerar interferência com a atividade da proteína. Um novo plasmídeo foi 
construído utilizando o vetor pUC19 contendo uma caude de histidinas na extremidade C-
terminal. Contudo, a expressão neste plasmídeo também não produziu quantidades suficientes 
de proteína para purificação. Uma nova abordagem será realizada ao clonar bcnK num vector 
contendo um péptido sinal, secretando BcnK para o espaço perisplásmico sem a componente 
lipidica N-acil-S-sn-1,2-diacilcerilcisteína, permitindo a solubilização da proteína. 
 De forma a investigar o papel de BcnK na resistência a antibióticos exibida por K. 
pneumoniae, tentou-se inativar bcnK no genoma bacteriano por duas metodologias, através de 
mutagénese dirigida não marcada, o que permitiria a obtanção de um mutante de eliminação 
isogénico, e através de mutação por inserção, por recurso aos plasmídeos construídos neste 
trabalho, pDG2 e pDG9, respetivamente. No entanto, não foram obtidos mutantes por quaiquer 
dos métodos, tendo-se obtido mutantes merodiplóides apenas na estratégia de inativação por 
mutagénese dirigida não marcada. Assim, em alternativa, procurou-se testar a essencialidade 
de BcnK por expressão de bcnK sob o controlo de um promotor induzível por ramnose. Contudo, 
foi necessário testar a funcionalidade deste promotor em K. pneumoniae. Para o efeito, utilizou-
se o vetor pSCrhaB2-e-GFP, que tem um promotor induzível por ramnose fundido 
transcricionalmente com o gene GFP (green fluorescent protein), o qual permite a deteção da 
sua expressão por fluorescência. Conjugou-se em K. pneumoniae, a qual foi crescida em 0.2% 
e 0.5% de ramnose e 0.5% glucose, respetivamente, tendo-se registado fluorescência na 
presença das diferentes concentrações de ramnose e, por outro lado, a ausência de 
fluorescência na presença de glucose, o que sugere o correto funcionamento do promotor no 
hospedeiro K. pneumoniae. Um fragmento de bcnK foi então clonado no vetor suicida contendo 
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um promotor induzível por ramnose pSC200, dando origem a pDG10, sendo este posteriormente 
conjugado em K. pneumoniae. Os transconjugantes obtidos foram crescidos em meio M9 
contendo 0.5% de ramnose (condições permissivas) ou glucose (condições não permissivas). 
Em ambos os meios, observou-se crescimento, sugerindo que bcnK não é um gene essencial à 
viabilidade de K. pneumoniae, pensando-se ainda que a expressão de bcnK na presença de 
glucose, ainda que em níveis basais, poderá ser suficiente para suportar a viabilidade de K. 
pneumoniae. Informação recolhida durante a pesquisa bibliografica sugere que BcnK intervem 
ao nivel da cadeia de transporte eletrónico, sendo a expressão de BcnK suprimida em 
anaerobiose. Desta forma, numa tentativa de se desligar a cadeia de transporte eletrónico, 
tentou-se mutagenizar bcnK em condições de anaerobiose. 
 Alternativamente, testou-se o papel de BcnK na resposta da célula ao stress oxidativo, 
usando para o efeito um plasmídeo com um gene repórter que codifica para uma proteína 
luminescente, a luciferase. Os resultados preliminares mostram o aumento da expressão de 
PbcnK::luxCDABE e PoxyR::luxCDABE (controlo positivo) nas condições testadas, sem grandes 
diferenças aparentes. No entanto, pretende-se utilizar no futuro a construção PwaaE::luxCDABE 
como controlo negativo, pois é previsto que a expressão de waaE não seja induzida por stress 
oxidativo. 
 O mutante de B. cenocepacia ΔBcnAΔBcnB foi complementado com o plasmídeo pDG1 
expressando BcnK para verificação da possibilidade de recuperação do fenótipo em relação à 
estirpe selvagem. Verificou-se que a complementação com BcnK conduz a níveis de CMI 
similares aos verificados com a estirpe selvagem, no entanto o mesmo resultado foi obtido 
quando se introduziu apenas o vetor (controlo), sugerindo que um efeito inespecífico. No entanto, 
bcnK será clonado no vetor pSCrhaB2, vetor este utilizado originalmente nos estudos de 
complementação em B. cenocepacia. 
 O alinhamento das sequências aminoacídicas de BcnK e BcnA por recurso à ferramenta 
Clustal Omega demonstrou que os resíduos Val107 e Glu118 de BcnK parecem corresponder 
aos resíduos Asp82 e Asp93 de BcnA, respetivamente, que foram demonstrados como 
essenciais para a ligação de BcnA a antibióticos. Apesar destas evidências in silico, a intervenção 
dos resíduos correspondentes em BcnK ao nível da ligação com antibióticos permanece por 
demonstrar experimentalmente. 
 A análise de polimorfismos de BcnK por pesquisa de homologia nas bases de dados 
internacionais, restringindo a busca ao género Klebsiella, seguida pelo alinhamento das 
respetivas sequências aminoacídicas, demonstrou que BcnK é altamente conservada neste 
género (99 a 81% de homologia), contudo desconhece-se ainda a influência das diferenças 
registadas na função biológica exercida pela proteína a nível celular. 
 O estudo da conservação de genes vizinhos de bcnK por análise de sintenia foi realizado 
a partir da ferramenta SyntTax. Os resultados obtidos permitiram observar a conservação do 
locus genético deste gene entre as várias espécies testadas. Em algumas espécies, o gene de 
BCNs encontra-se associado ao gene que codifica para o citocromo b561 (CybB). Contudo, não 
foi encontrada sintenia para Enterococcus faecium, Streptococcus pyogenes e Acetobacterium 
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woodii, nos quais se registou a ausência de BCNs e CybB. Estas espécies bacterianas são 
conhecidas por não possuírem cadeia de transporte eletrónico funcional e por serem anaeróbios 
restritos. Assim, considerando a globalidade dos resultados obtidos, propõe-se um modelo da 
funcionalidade das BCNs, sugerindo-se que estas proteínas participam no transporte ou 
sequestro de compostos hidrofóbicos, tais como quinonas isoprenóides ou vitamina E, 
especificamente no meio extracelular, por ação de BcnA, ou no meio periplásmico, por ação de 
BcnB ou BcnK. Estes compostos hidrofóbicos são transportados até CybB, onde são reduzidos, 
e posteriormente transportados para o meio extracelular e/ou periplásmico, atuando como 
agentes antioxidantes. 
Fica, no entanto, por demonstrar experimentalmente este papel.  
 
Palavras-chave: BCNs; YceI; Klebsiella pneumoniae; kp52.145; Proteína sequestradora 
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ABSTRACT 
Antibiotic resistant bacteria have become one of the greatest threats to modern society, 
especially those bacteria that resist multiple antibiotics (referred to as multidrug resistant; MDRs). 
Although most well known resistance mechanisms operate within bacterial cells, recent evidence 
suggests extracellular mechanisms. One of such mechanisms involves bacterial lipocalins 
(BCNs), which are secreted proteins that capture hydrophobic antibiotics in the extracellular 
space. BCNs are widely distributed in bacteria. Klebsiella pneumoniae, a Gram-negative enteric 
bacterium, possesses a BCN ortholog. Klebsiella species cause hospital and community-acquired 
infections and antibiotic resistance is in part due to the spread of β-lactamases. In this thesis, I 
cloned, expressed and purified a K. pneumoniae kp52.145 BCN (BcnK). Recombinant BcnK 
proteins were employed in antibiotic protection assays using Pseudomonas aeruginosa PAO1 
against polymyxin B (PmB) as a model system. Full-length recombinant BcnK was unstable and 
formed aggregates that complicated its quantification. However, this protein caused an increase 
of 65.5% in the OD600 of P. aeruginosa in the presence of sublethal amount of PmB. Other bcnK 
constructs were made, but either lacked activity or could not be purified. A bcnK chromosomal 
deletion was attempted using protocol to proceed unmarked deletion and another one to mutate 
by inserting a polar gene cassette. No mutants were obtained in both cases. K. pneumoniae 
kp52.145 bcnK gene expression was placed under control of a rhamnose-inducible promoter, but 
the resulting constructs did exhibit the expected growth defect, showing the same growth 
phenotype irrespective of the presence of rhamnose (permissive condition) or glucose (non-
permissive condition), suggesting that bcnK is not essential for K. pneumoniae viability. I also 
investigated the regulation of bcnK gene expression. Preliminary results suggest that bcnK 
expression is upregulated under different concentrations of paraquat, a compound that stimulates 
the production of oxygen radicals. Recombinant bcnK was used to complement a ΔbcnAΔbcnB 
Burkholderia cenocepacia mutant by assessing the restoration of rifampicin resistance to parental 
levels. However, increased resistance could only be attributed to the plasmid vector control but 
not to the plasmid expressing BcnK. Alignments done using amino acid sequence for BcnK and 
BcnA from B. cenocepacia J2315 showed two residues, Val107 and Glu118 of BcnK to 
correspond to Asp82 and Asp93 of BcnA, respectively. Previous reports have shown that these 
residues, in BcnA, are these residues were shown to be crucial for antibiotic binding. BCN 
genomic studies showed a highly conserved protein (99 to 81% homology) among Klebsiella 
species. Synteny and BLASTp results showed that in some species BCNs are associated with a 
cytochrome b561 (cybB) gene. However, both BCNs and cybB genes are absent in strict 
anaerobes. I suggest a model of BCNs cellular function that involves the hijacking of hydrophobic 
compounds, such as isoprenoid quinones, and their transport to the membrane where these 
compounds are reduced and further transported in the extracellular and/or periplasmic space 
acting as antioxidants.  
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CHAPTER I – INTRODUCTION 
1.1. The Antibiotic Crisis 
Since the discovery of penicillin, the first known antibiotic, by Alexander Fleming in 1928, 
mankind has relied on this and other antibacterial molecules for the treatment of bacterial 
infections. The antibiotics are molecules used in the treatment and prevention of infections caused 
by bacteria. However, the “antibiotic era” might come to an end as the majority of the clinically 
available antibiotics are becoming useless to treat bacterial infections (Figure 1.1) caused by 
multidrug resistant (MDRs) Gram-positive and Gram-negative strains (Llor & Cots, 2009). This 
scenario, named the “post-antibiotic era” is considered one of the greatest threats for mankind 
(WHO, 2014; WEF, 2015). Despite the investment and incentives to research to identify new 
antimicrobial molecules in the last years (Piddock, 2012), there are considerable challenges to 
bring them to the market resulting on a long and fastidious process (Nathan, 2004; Wright, 2015). 
Aggravating this situation, the interest of pharmaceutical companies to search for new molecules 
has decreased in the last years, resulting in only a few newly approved and reliable drugs 
(Spellberg, 2011). 
Antibiotic molecules inhibit the growth or kill bacteria with minimum impact on the human 
body. They have different mechanisms of action for which they are categorized in different 
classes. For instance, (i) β-lactams interfere with cell wall synthesis, (ii) macrolides inhibit protein 
synthesis, (iii) fluoroquinolones interfere with nucleic acids synthesis, (iv) trimethoprim inhibits 
metabolic pathways and (v) polymyxins disrupt bacterial membrane. In some cases, bacteria are 
capable of overcoming this toxicity through several mechanisms which give rise to resistant 
strains. The antibiotic therapy represents a stressful environment for a sensitive bacterial 
community, and resistant subpopulations are selected and ultimately able to prevail and 
proliferate in the community giving rise to one or more resistant strains. In clinical microbiology, a 
strain is defined as resistant, susceptible or intermediate by comparing the minimum inhibitory 
concentration (MIC). This is the minimal antibiotic concentration at which bacterial growth is 
inhibited under standardized conditions in vitro (Turnidge & Paterson, 2007), with the predefined 
susceptibility “breakpoint” of the tested species.  
In the past, the bulk of research efforts in antibiotic resistance focused on bacterial cellular 
functions associated with decreased susceptibility. These included (i) modification of the 
antibiotics target due to chromosomal mutations, making it unrecognizable to the antibiotic, (ii) 
production of enzymes that breakdown or modify antibiotic molecules inactivating them, (iii) 
extrachromosomal elements from other bacteria, such as plasmids, transposons and integrons, 
which can be accumulated on a single or several strains expressing proteins that inactivate the 
antibiotic affect, (iv) efflux pumps responsible for expelling several types of antibiotics from inside 
the cell (v) and decreasing membrane permeability to antibiotics reducing the access to their 
targets  (Levy & Marshall 2004; Tenover, 2006; Alekshun et al., 2007). DNA analysis of human 
bacterial microbiota revealed identical genes harbored by major bacterial pathogens (Sommer et 
al., 2009) and similar genes responsible for the present modern antibiotic resistance were found 
in the environment and in samples dating back millions of years (Forsberg et al., 2012; Bhullar et 
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al., 2012) suggesting a great adaptation capacity to resist the action of antibiotics whose existence 
predates their use in clinical therapies (Iredell et al., 2016) (Figure 1.1). 
Compounding the above-described mechanisms of resistance, other factors not related 
to bacteria adaptation may influence the rise of resistance. Indeed, the necessary MIC to be 
achieved on an infected patient, regardless of the drug dosing (pharmacokinetics), may not 
always be attained in the patient (Andersson & Hughes, 2014), especially at the site of infection, 
since antibiotics do not readily diffuse inside inflamed tissues. Also, the MIC depends on the 
population density at the site of infection (inoculum effect), as bacteria produce antibiotic 
resistance proteins that concentrate locally, destroying more antibiotic than an individual cell 
(Martínez et al., 2015). Thus, bacteria may be exposed to sub-lethal antibiotic concentrations, 
promoting the rise and selection of resistance. 
To reduce the incidence of MDRs, new strategies of drug administration are being 
implemented in hospital facilities (Baquero et al., 2011; Spellberg et al., 2013). However other 
measures must also be applied to increase the efficiency of old and currently used drugs. So it 
falls on scientific community to research for new antimicrobial drugs or augment currently licensed 
antibacterial drugs (Piddock, 2012) and generate a deep understanding of biological and 
molecular mechanisms of antibiotic action and resistance (Wright, 2015). 
 
 
 
 
 
 
Figure 1.1 – Timelines of antibiotic introduction (above) and bacterial antibiotic resistance (below). *Not in clinical use; Ampicillin 
hydrolyzing (AmpC); Cefotaximase (CTX-M); Imipenemase (IMP); Klebsiella pneumoniae carbapenemase (KPC); Methicillin resistant 
Staphylococcus aureus (MRSA); New Delhi metallo-β-lactamase (NDM); Penicillin resistant S. aureus (PRSA); β-lactam hydrolyzing 
enzymes (TEM, SHV, OXA); Vancomycin resistant Enterococci (VRE); Vancomycin resistant S. aureus (VRSA); Verona integron 
encoded metallo β-lactamase (VIM) (Iredell et al., 2016). 
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1.2. A new resistance mechanism 
1.2.1. Extracellular antibiotic hijacking 
Recent work in Valvano’s laboratory has identified a group of previous described proteins 
known as bacterial lipocalins, herein bacteriocalins (BCNs; formerly known as YceI), which 
possess the ability to bind and hijack antibiotics in the extracellular space rendering them 
ineffective, thus augmenting the MIC value. The initial study was carried out using Burkholderia 
cenocepacia K56-2, an opportunistic pathogen responsible for causing chronic infection on 
immunocompromised patients (O’Neil et al., 1986; Poe et al., 1977), especially in those with cystic 
fibrosis (CF) (Isles et al., 1984). B. cenocepacia K56-2 belongs to B. cepacia complex (Bcc), a 
group of 20 closely related species, phenotypically similar but genetically discrete (De Smet et 
al., 2015) of motile, aerobic, rod-shaped, non-spore forming Gram-negative β-Proteobacteria. In 
that study, data based on the phenotypes of B. cenocepacia wild-type and two mutants defective 
in the production of BCN paralogues, BcnA (BCAL3311) and BcnB (BCAL3310) (El-Halfawy & 
Valvano, unpublished data) indicated that these proteins, and in particular BcnA, not only hijack 
antibiotics but their function could be inhibited by vitamin E. 
 
BCNs are proteins synthesized and secreted into bacterial milieu leading to increased 
MIC but also virulence augmentation. The described mechanism of action consists on binding to 
antibiotics rendering them ineffective. This extracellular scavenging of antibiotics by BCNs 
represents a novel mechanism (Figure 1.2) of intrinsic bacterial resistance. Moreover, as some 
of these proteins homologous are naturally secreted into the extracellular milieu, its effect is not 
restricted to BCNs producing bacteria. Other more susceptible bacteria present on the milieu, of 
the same or different species, can benefit from this protection and thus, this mechanism of 
Figure 1.2 – BCNs antibiotic resistance action model. Depending on the homologue, BCN is shown in 
different cellular localizations, bound to antibiotics. 
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resistance can act at the community level (El-Halfawy & Valvano, 2012; 2013). The same authors 
also demonstrated that the addition of purified B. cenocepacia BCNs is also capable to increasing 
the virulence of other bacteria species in in vivo assays with Galleria mellonella. Further, BCNs 
were also capable to protect Pseudomonas aeruginosa, when injected in mice, against Polymyxin 
B (PmB) action. It was also observed that BCNs expression is upregulated in response to 
antibiotic oxidative stress conditions (El-Halawy & Valvano, 2013). 
 
1.2.2. Bacteriocalins (BCNs) 
BCNs consist on a large family of low-molecular weight proteins with more than 5400 
homologous distributed in both Gram-negative and positive bacteria (Bishop, 2000; Smart, 2016). 
Most members of this family are annotated as “conserved hypothetical proteins” referred to as 
YceI. Apart from a few examples of cytoplasmic BCNs from Campylobacter jejuni and Chlorobium 
tepidum, most of BCN coding regions possess a type-1 or type-2 signal peptide, suggesting these 
proteins are secreted into the extracellular space in Gram-positives and into the periplasmic space 
in Gram-negative bacteria, or they are covalently modified on the N-terminal with a N-acyl-S-sn-
1,2-diacylglycerylcysteine moiety, enabling the protein to anchor on the inner leaflet of the outer 
membrane as lipoproteins (Bishop, 2000) (Figure 1.3).  
 
The BCN’s expression in Escherichia coli was shown to depend on S sigma factor 
(RpoS), which activates gene transcription under several environmental stressful conditions, such 
as starvation, osmotic stress (Bishop, 2000) and alkaline pH (Stancik et al., 2002). Other example 
of induced expression occurs in the homologous Helicobacter pylori BCN, which is overexpressed 
under low pH contributing for bacterial survival during a stomachic infection (Sisinni et al., 2010). 
Figure 1.3 – BCNs subcellular localization in bacteria, showing BCNs in cytosol, anchored on inner and outer 
membrane, in periplasmic space. Its localization depends on the presence or absence and type of leader peptide 
present on BCN coding region (Image adapted from Bishop, 2000). 
 
Bacteriocalins 
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There are also indications that BCNs homologs from different bacteria possess different 
functionalities based on the capacity to bind to different molecules, such as fatty acids and amines 
(Sisinni et al., 2010), isoprenoid lipids (Handa et al., 2005; Vincent et al., 2010), chlorophenoxy 
herbicides (Benndorf et al., 2004), lipophilic antibiotics (El-Halfawy & Valvano, 2013), and fat-
soluble vitamins such as α-tocopherol (vitamin E) and menaquinone (vitamin K2) (El-Halfawy & 
Valvano, unpublished). 
The BCNs three-dimensional fold generally consists of an extended, eight to nine 
stranded antiparallel β-sheet, folding back on itself forming a β-barrel with one closed end, 
establishing a pocket inside and followed by a C-terminal α-helix (Figure 1.4). The lipophilic 
ligands are hosted inside the pocket of the β-barrel structure (Bishop, 2000; Handa et al., 2005). 
However, BCNs molecular modeling suggests two binding ways: (i) one by antibiotic polar 
interactions, with several amino acids residues, at the rim of the BCNs pocket, and another (ii) for 
more lipophilic interactions deeper into its pocket. Aromatic moieties may also play a role in 
molecular recognition of these proteins (El-
Halfawy & Valvano, unpublished). 
Like many other components present 
on the bacterial envelope (BCNs are uniquely 
synthesized by bacteria and are cell surface-
exposed), BCNs are recognized as 
pathogen-associated molecular patterns 
(PAMPs). The N-acyl-S-sn-1,2-
diacylcerylcysteine modification on BCNs N-
terminus stimulates an immune response 
through CD14 receptors recognition in 
macrophages plasmatic membrane surface 
(Medzhitov & Janeway, 1997; Hoffmann et al., 1999), resulting in activation of immune cells 
leading to inflammatory responses (Brightbill et al., 1999; Aliprantis et al., 1999). BCNs stimulate 
innate and adaptive immune systems, as also indicated by the presence of BCNs antibodies in 
patients' sera (Scott et al., 2013; Yoder-Himes et al., 2010; Upritchard et al., 2008). 
BCNs cellular function is still unclear. Even with all the available information, is not 
possible to predict the binding preference of the BCN orthologs. In this study, we focused on the 
Klebsiella pneumoniae BCN homolog. K. pneumoniae is an opportunistic pathogen responsible 
for more than 15% of Gram-negative infections in hospital intensive care units (ICUs) in the United 
States (Lockhart et al., 2007), and the main cause of nosocomial infections caused by the 
Enterobacteriaceae in hospitals (Chien Ko et al., 2002; Sanchez et al., 2013) and community 
centers (Carpenter, 1990). Rice (2008) referred K. pneumoniae as one of the ESKAPE bugs, 
along with Enterococcus faecium, Staphylococcus aureus, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter species. These bacteria are responsible for the 
largest share of nosocomial infections as well representing paradigms of pathogenesis, 
transmission and, most importantly, antibiotic resistance (Rice, 2008). 
Figure 1.4 – Polyisopreniod-binding protein TT1927b 
(protein data bank code 1wub), an example of YceI-like 
crystal structure with a polyisoprenoid within the β-barrel 
structure, obtained from Thermus thermophiles HB8. 
(http://www.ebi.ac.uk/pdbe/entry/pdb/1wub). 
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1.3. A rising multidrug resistance bacterium 
1.3.1. The Klebsiella genus 
The Klebsiella genus includes nonmotile, capsule forming, rod shaped Gram-negative 
bacteria of the Enterobacteriaceae family and belongs to the γ-Proteobacteria. They were named 
after the German microbiologist Edwin Klebs. This bacterium is human commensal normally 
found among the skin and gastrointestinal tract microflora (Bagley, 1985). It can also be found in 
sewage, polluted waters, soil and plants. Some strains associated with plant roots have shown to 
fix nitrogen, converting into ammonia (Postgate, 1998) through the expression of the nitrogenase 
enzyme complex, encoded by the nif gene cluster (Ausubel et al., 1983; Wang et al., 2013). 
Consequently, those strains have the potential to be used for agriculture (Riggs et al., 2001; 
Temme et al., 2012). Through genetic comparison of 16S rRNA and rpoB gene sequences, 
Klebsiella genus can be organized in three distinct clusters. Cluster I: K. pneumoniae containing 
three sub-species; K. pneumoniae subsp. pneumoniae; K. pneumoniae subsp rhinoscleromatis 
and K. pneumoniae subsp. ozaenea. 
Cluster II containing K. ornithinolytica, K. 
planticola, K. trevisanii and K. terrigena. 
And cluster III containing K. oxytoca 
(Drancourt et al., 2001). Klebsiella species 
are characteristic for producing a thick 
polysaccharide capsule (Figure 1.5), giving 
their colonies a mucoid appearance. The 
capsule synthesis represents a key 
element to Klebsiella’s virulence, as 
capsulated strains exhibits higher virulence 
than capsule defective mutants (Simoons-
Smit et al., 1986). The capsules are 
generally composed by polysaccharides in 
repeating units of three to six sugars and 
uronic acids giving rise to 77 varieties (Li et al., 2014; Follador et al., 2016), known as K-antigens, 
enabling to distinguish Klebsiella strains into serotypes (Podschun & Ullmann, 1998). Within these 
K-antigens varieties, strains harboring K1 and K2 capsules types exhibit hypermucoviscous 
phenotypes due to the elevated production of capsule and are associated with hypervirulence of 
Klebsiella pneumoniae strains (Follador et al., 2016), although not all of K1 and K2 strains are 
virulent (Kauffmann, 1949; Mizuta et al., 1983). Klebsiella polysaccharide capsule prevents 
bacteria from being recognized by innate immune defenses, avoiding phagocytosis and inhibiting 
the complement activation (Domenico et al., 1994). The polysaccharides also inhibit 
differentiation and functional capacity of macrophages in in vitro assays (Yokochi et al., 1979). 
The O-antigen, the outermost part of lipopolysaccharides (LPS), represent another virulence 
factor of the Klebsiella genus, as it activates the complement system, causing C3b molecule 
deposition far from the bacterial cell membrane, thus preventing the insertion of the complement’s 
Figure 1.5 - Klebsiella pneumoniae (dark violet) surrounded by 
its capsule (white) grown in skim milk broth and stained with 
Anthony’s capsule stain.  (Roxana B. Hughes, University of 
North Texas, Denton, TX) 
Bacteria Capsule 
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membrane attack complex into the bacteria cell envelope (Podshun & Ullmann, 1998).  Additional 
virulence factors in Klebsiella include: (i) adhesins (pili, fimbriae) allowing the bacteria to bind to 
the host cell and catheters (Schroll et al., 2010), (ii) siderophores, which are secreted low-
molecular-weight, high-affinity iron chelators scavenging iron bound to host proteins (Podshun & 
Ullmann, 1998), (iii) biofilm formation, which provides increased antibiotic resistance, and (iv) 
urease production, which, by hydrolyzing urea increases the pH in the infection locale, leading to 
precipitation and encrustation of organic salts and facilitating the formation of biofilms (Clegg & 
Murphy, 2016). However, there is a significant heterogeneity in Klebsiella strains and not every 
one of these factors plays the same critical role in virulent strains (Paczosa & Mecsas, 2016). The 
virulence factors used by Klebsiella are not focus in this work, so the reader is referred to recent 
reviews for additional information (Li et al., 2014; Paczosa & Mecsas, 2016). 
 
1.3.2. Klebsiella pneumoniae 
1.3.2.1. Epidemiology 
K. pneumoniae is the most prevalent species of nosocomial agents that cause 
pneumonia, followed by Klebsiella oxitoca (Jarvis et al., 1985). Klebsiella can rapidly spread in 
healthcare facilities by direct contact with infected personal or other patients and cause hospital 
outbreaks (ECDC, 2014) and community-acquired pneumonias (Paczosa & Mecsas, 2016). Apart 
from pneumonia, K. pneumoniae is also frequently responsible for urinary tract infections, being 
the second most frequent cause after E. coli (Czaja et al., 2007; Lorente et al., 2005). K. 
pneumoniae primary infections on lungs and bladder can spread into the blood causing 
bacteremia, resulting in high rates of morbidity and mortality (Clegg & Murphy, 2016). Individuals 
suffering from diabetes mellitus, neuropathic bladders, chronic renal insufficiency, chronic 
obstructive pulmonary diseases, immunocompromised patients and alcoholics are generally 
considered risk groups for K. pneumoniae infections (Montgomerie, 1979; Ko et al., 2002; Clegg 
& Murphy, 2016), although K. pneumoniae hypervirulent (HV) strains were previously reported to 
cause life-threatening infections on healthy individuals (Shon & Russo, 2012; Shon et al., 2013). 
Liver infections are likely initiated from a breach in host defenses in the gastrointestinal tract 
(Paczosa & Mecsas, 2016). These type of strains are primarily responsible of causing liver 
abscess and are able to spread through metastasis causing further complications such as 
meningitis, endophthalmitis, necrotizing fasciitis and abscesses in other tissues (Siu et al., 2012) 
and its prevalence seems to be restricted mainly in Taiwan and Southeast Asia (Chung et al., 
2007; Siu et al., 2012). Infections caused by hypervirulent strains are treatable through very 
aggressive therapies, although these may not prevent catastrophic disabilities on infected 
patients (Fang et al., 2000). 
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1.3.2.2. K. pneumoniae MDRs overview 
Much like other important pathogens, K. pneumoniae MDRs strains have emerged due 
to several mechanisms such as efflux pumps (Ogawa et al., 2005), chromosomal mutations and 
plasmid-borne resistance (George et al., 1995; Hudson et al., 2014). Two major types of 
resistance have been commonly observed in K. pneumoniae. One is the expression of extended-
spectrum β-lactamases (ESBLs) capable to hydrolyze cephalosporins and monobactams. The 
other mechanism which is considered more concerning is the expression of carbapenemases. 
These are β-lactamases with the ability to hydrolyze carbapenems. First discovered in 1996 (Yigit 
et al., 2001), the K. pneumoniae carbapenemases-producing strains (KPCs) render useless a 
broad spectrum of antibiotics like penicillins, all cephalosporins, monobactams, β-lactamases 
inhibitors and last-resort carbapenems (Papp-Wallace et al., 2010). The functional Ambler 
classification divides β-lactamases in four major classes (class A to D) based upon their amino 
acid sequence homology (Hall & Barlow, 2005). β-lactamases from classes A, C and D have 
serine in their active site, while class B possesses zinc (Hall & Barlow, 2005; Paterson, 2006). In 
this classification, carbapenemases are included on classes A, B and D, while ESBLs are strict 
to class A (Queenan & Bush, 2007). All KPCs fall into class A and are divided 16 different variants 
(KPC-2 to KPC-17), being KPC-2 and KPC-3 the most prevalent (Hirsch & Tam, 2010; Wang et 
al., 2014). Additional types of carbapenemase were also found in K. pneumoniae strains such as 
metallo-β-lactamases (MBL), which fall into Class B and OXA-β-lactamases, which fall into class 
D (Pitout et al., 2015). Irrespective of the type of carbapenemases they encode carbapenemase-
producing isolates are usually termed carbapenem-resistant Enterobacteriaceae (CRE) (Paczosa 
& Mecsas, 2016). Only few antibiotics, such as tigecycline and polymyxins, can be used to treat 
Figure 1.6 - Epidemiological incidence of several types of KPCs producer types by country of origin (Munoz-Price et al. 
2013). 
9 
 
infections by CRE bacteria, but with variable degree of success (Urban et al., 2008). Therefore, 
these bacteria cause a high mortality rate among patients with bloodstream infections (Munoz-
Price, 2013; Clegg & Murphy, 2016). 
KPC genes possess a great potential to spread horizontally as some of them are encoded 
on transposons and often found present on several types of plasmids (Queenan & Bush, 2007). 
Horizontal transfer is not restricted to Klebsiella as KPC genes have been reported on other 
Enterobacteriaceae, including E. coli, Enterobacter species, Salmonella enterica, Proteus 
mirabilis, Citrobabacter freundii (Queenan & Bush, 2007; Bush et al., 1995; Villegas et al., 2005) 
and Pseudomonas species (Munoz-Price et al., 2013). K. pneumoniae KPC ST258, defined by 
multilocus sequence typing (MLST) of 7 loci, played a major role in disseminating its associated 
KPC enzymes worldwide (Munoz-Price et al., 2013). More detailed information on ST258 and 
genes concerned in MRDs dissemination can be found in recent reviews (Iredell et al., 2016; 
Paczosa & Mecsas., 2016). 
KPC strains incidence has been steadily increasing worldwide (Munoz-Price et al., 2013; 
Iredell et al., 2016) (Figure 1.6), as well as ESBLs producing K. pneumoniae (Boucher et al., 
2009), making urgent to find new ways to successfully treat infections caused by these MDRs 
bacteria. 
 
1.4. The present work objectives 
In this dissertation, I will explore the role of BCNs ortholog of K. pneumoniae kp52.145 
virulent strain, to confer an antibiotic resistance mechanism as described for B. cenocepacia (El-
Halfawy & Valvano, 2013). In doing so, I aim to demonstrate that BCNs provide general resistance 
mechanism that can be exploited by important antibiotic-resistant pathogens. Initially I will assess 
the protection capacity of a recombinant K. pneumoniae BCNs protein. Simultaneously, I will 
attempt to delete BCNs gene from K. pneumoniae chromosome. Also, the regulation properties 
of the same gene under oxidative stress will be evaluated. Finally, I will perform in silico studies 
of K. pneumoniae BCNs by comparing with other BCNs from different bacteria. Additionally, 
synteny studies will be performed. 
Here, I will describe all the developed work done until the submission of this dissertation. 
Additional experimental work is still underway and new data generated will be presented during 
the public defense. 
 
CHAPTER II – MATERIALS AND METHODS 
2.1. General protocols 
2.1.1. Bacterial strains and growth conditions 
Strains and plasmids used for this thesis are listed on Table S1 (see Supplementary data 
on CHAPTER V). Bacteria were grown at 37˚C, 180 rpm, in Difco™ LB broth. Rhamnose 
conditional mutants were grown on M9 minimal medium (42 mM Na2HPO4, 8 mM NaCl, 10 mM 
NH4Cl supplemented with Casamino Acids (80 µg/mL), vitamin B1 (10 µg/mL), tryptophan (40 
µg/mL), CaCl2 (20 µM), MgSO4 (200 µM), and 0.5% (w/v) glucose or 0.5% (w/v) rhamnose when 
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required. Mueller-Hinton media cation adjusted with 10 mg/L Mg2+ and 20 mg/L Ca2+, final 
concentration, was used for MIC determinations. Each medium were added with antibiotics 
trimethoprim (50 µg/mL for E. coli strains; 100 µg/mL for K. pneumoniae), ampicillin (100 µg/mL), 
tetracycline (100 µg/mL for B. cenocepacia; 30 µg/mL for E. coli; 12.5 µg/mL for K. pneumoniae), 
kanamycin (40 µg/mL) final concentrations when required.  
 
2.1.2. General molecular techniques  
K. pneumoniae kp52.145 genomic DNA extraction was carried out using Genomic DNA 
Mini kit (Invitrogen), chromosomal amplicons were generated by PCR using HotStar Hifidelity 
polymerase Kit (Qiagen), using 20% Q-solution final concentration and thermocycled at the 
following temperatures: 5 min at 95˚C; 35 cycles of 30 s at 95˚C, 30 s at 55˚C and 1 min 72˚C 
and final extension 10 min at 72˚C and purified by QIAquick PCR purification kit (Qiagen). Plasmid 
extractions were carried out using QIAprep Spin Miniprep Kit (Qiagen). DNA restriction 
endonuclease digestions, plasmid dephosphorylation, ligations reactions and agarose gel 
electrophoresis were performed according to standard techniques (Sambrook et al., 1990). 
Restriction enzymes and Antarctic phosphatase were purchased from New England BioLabs, T4 
DNA ligase from Roche Diagnostics. DNA transformation with E. coli strains was carried out by 
calcium chloride method (Cohen et al., 1972). Colony-PCR (cPCR) were carried out with Taq 
polymerase kit (Qiagen) with the following parameters: 3 min at 95˚C; 45 cycles of 15 s at 95˚C, 
30 s at 56˚C and 1 min 72˚C; and a final extension at 72˚C for 10 min. PCR products were 
screened on 0.7% (w/v) agarose gels. Gene sequence of positive transformants was verified by 
sequencing. All designed primers and respective restriction enzymes are listed on Table S2. 
 
2.1.3. Biparental conjugation 
The various constructed vectors from all other procedures, which were transformed in E. 
coli DH-5α and E. coli GT115, were extracted and transformed into diaminopimelic acid (DAP) 
dependent E. coli β2163, capable to mobilize the vectors into the recipient strains, such as K. 
pneumoniae or B. cenocepacia, by biparental conjugation. The biparental conjugations were 
carried out using 2,6-Diaminopimelic acid bought from Sigma-Aldrich®. 
 Mobilization of the vectors was performed by growing overnight of recipient strain, with 
180 rpm orbital shaking and the donor strain without shaking. Next day, both strains were pelleted 
by centrifugation at 4000 rpm for 20 min, washed in 5 mL of 10 mM MgSO4, pelleted again and 
resuspended in 500 µL 10 mM MgSO4. A mixture of 100 µL of each strain patched in LB agar 
supplemented with 0.3 mM of DAP final concentration, incubated overnight at 37˚C. Next day, 
serial dilutions were made, until 10-4, from the recovered patched biomass and plated on LB 
without the addition of DAP and with the appropriate antibiotic. The grown colonies were screened 
by cPCR and/or luminescence on UVP (BioSpectrum® AC Imaging System). 
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2.2. K. pneumoniae BCN studies 
2.2.1. Cloning, expression and purification of K. pneumoniae kp52.145 BCN 
K. pneumoniae kp52.145 yceI nucleotide sequence (GenBank ID: FO834906.1) and YceI 
amino acid sequence (GenBank ID: CDO15049.1) was retrieved from National Center for 
Biotechnology Information (NCBI) using Basic Local Alignment Search Tool for proteins 
(BLASTp) algorithm, deploying as query sequence the protein sequence of the putative exported 
protein from B. cenocepacia J2315 (GenBank: CAR53634.1) (Table S3). 
To facilitate the differentiation from other BCN orthologues, such as B. cenocepacia’s 
BcnA and BcnB, the gene encoding K. pneumoniae’s BCN (yceI) will be referred to as bcnK and 
its respective encoded protein will be mentioned as BcnK. 
bcnK was amplified by PCR with (primers Q-775 and Q-776) and without (Q-873 and Q-
776) its signal peptides, cloned into pDA-CTHis, which contains an N-terminal hexahistidine tag 
(His-tag), originating pDG1 and pDG5, respectively. To clone into pET28a (+) isopropyl thiol-β-D-
galactoside (IPTG) inducible vector, bcnK was amplified without its signal peptide and encoding 
an N- and C-terminal His-tag (Q-873 and Q-880) giving rise to pDG7. Also, bcnK was amplified 
without signal peptide and coding for a N-terminal His-tag (Q-873 and Q-895), and cloned into 
pET28a (+). Primers (Q-907 and Q-908) for bcnK cloning into pUC19 inducible vector were design 
without bcnK’s signal peptide and to contain a His-tag followed by a STOP codon on bcnK’s C-
terminal giving rise to pDG11. This last vector was point mutated by amplifying (Q-961 and Q-
962) to add an adenine base upstream of bcnK start codon and digested with DpnI overnight at 
37˚C afterwards, transformed into E. coli and the resulting colonies were selected in ampicillin. 
The generated amplicons and respective vectors were digested with restriction enzymes, listed 
on Table S2, ligated and transformed into E. coli DH-5α. IPTG inducible vectors were transformed 
into E. coli BL2. Overnight cultures induction were carried out using 0.05 mM IPTG, final 
concentration and further incubated for 3 h at 25˚C, centrifuged at 10,000 x g for 15 min at 4˚C, 
washed with Tris-buffer 50 mM, pH 7.4 and pelleted again, resuspended in Lysis buffer (Table S4 
A) and passed through One Shot (E1061, Constant System) at 18 ksi (124.1 GPa). The resulting 
lysate was centrifuged at 15,000 x g for 20 min at 4˚C for cell debris removal and to obtain the 
total protein fraction. Soluble and membrane protein fractions were obtained by centrifuging the 
total protein fraction at 30,000 x g for 45 min at 4˚C. BcnK purification was carried out by mixing 
the soluble fraction with coated Ni2+ Chelating Sepharose™ Fast Flow (GE Healthcare) beads 
overnight at 4˚C previously treated with equilibration buffer (Table S4 B). Next day, the 
supernatants were collected, labelled as Flow through, and the beads were washed with 
increasing concentration of imidazole (50 mM and 75 mM), eluted in 400 mM (Table S4 C) and 
dialyzed in 4 L of phosphate-buffered saline (PBS) overnight at 4˚C. In each step an aliquot was 
collected for further analysis. The dialyzed protein was filter sterilized with 0.45 µm Whatman™ 
(SPARTAN Syringe Filter) and conserved at -80ºC until used. The presence of the protein was 
confirmed by SDS-PAGE and Western-Blot. 
 
12 
 
2.2.2. SGS-PAGE & Western-blot 
 The various protein fractions obtained were boiled at 100˚C for 10 min, loaded in a 16% 
SDS-PAGE gel, run for 75 V for 35 min and 130 V for 2 h. For SDS-PAGE staining the gel were 
dyed with PAGE-Blue™ (Thermo Scientific) for 2 h and distained overnight. 
For Western-blot assays, the protein transfer was carried out using Biorad Trans-Blot® 
Turbo™ Kit into a nitrocellulose membrane for 20 min with 1.3 A and 25 V, blocked overnight at 
4˚C with Blocker™ Casein in TBS (Thermo Scientific). Next day, the membrane was washed with 
Tris-buffered saline (TBS), the primary antibody Anti-His Antibody (GE Healthcare Life Sciences) 
was added diluted 1:3000 and incubated at 4˚C for 2 h, washed three times with TBS, added the 
secondary antibody AlexaFluor® 680 anti-mouse IgG (Life Technologies) diluted 1:20000, 
incubated for 45 min, washed three times and checked at Li-cor (Odyssey®) at the wavelength 
of 700 nm. 
 
2.2.3. P. aeruginosa polymyxin B (PmB) protection assays 
The purified and dialyzed BcnK obtained from the expression of the various constructed 
vectors, were concentrated if required using Vivaspin 500 (3000 MWCO PES, Sartorius Stedim 
Biotech), quantified by NanoVue Plus™ Spectrophotometer. Overnight cultures of P. aeruginosa 
PAO1 were subcultured for 2 hours, OD600 adjusted to 0.04, loaded in a 100 well honeycomb 
plate along with 2; 1; 0.5; 0 µg/mL final concentration of PmB and 1.5 µM, final concentration, of 
purified BcnK. Controls were performed with the same antibiotic concentrations using PBS 
instead of purified BcnK. Each antibiotic concentration, with and without BcnK, was tested within 
triplicates. The OD600 was read each hour at 37ºC for 24 h on Bioscreen C (Oy Growth Curves 
Ab Ltd.).  
 
2.3. K. pneumoniae mutagenesis 
2.3.1. bcnK deletion in K. pneumoniae kp52.145 
 Unmarked deletion method was performed as previously described (Flannagan et al., 
2008). To delete bcnK, PCR amplifications of ≈ 300 bp flanking regions bcnK were performed (Q-
786 and Q-787; Q-788 and Q-789). Amplicons were digested with XbaI-XhoI and XhoI-EcoRI 
respectively and cloned into pGPI-SceI-2 digested with XbaI-EcoRI giving rise to pDG4. 
Simultaneously, it  was also created a vector containing ≈ 1000 bp flanking regions bcnK (Q-810 
and Q-811; Q-812 and Q-813), the amplicons were joined together using Ex Taq® DNA 
polymerase (TaKaRa) and ligated into pGEM®-TEasy resulting on the vector ΔyceI-pGEMT. The 
vector was digest with EcoRI, gel purified and ligated with pGPI-SecI-2 giving rise to pDG2. Each 
plasmid was introduced to wild type (WT) strain of K. pneumoniae kp52.145 by conjugation, 
separately, and selected with trimethoprim. The resulting conjugants were subjected to a new 
conjugation with pGPI-SceI-SacB and selected through tetracycline resistance. 
Insertional inactivation was performed by cloning an bcnK internal fragment with 297 bp 
(Q-902 and Q-903) into suicide vector pGPΩTp (Flannagan et al., 2007) which contains dhfr 
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flanked with Ω-fragments, which when conjugated into K. pneumoniae, creates a polar mutation 
stopping bcnK transcription. The constructed vector was named pDG9. 
The procedures described above were carried out in both aerobic and anaerobic 
conditions. For anaerobic conditions, samples were manipulated and incubated in Whitley A35 
Anaerobic Workstation under an atmosphere composed by 10% CO2, 10% H2 and 80% N2. 
 
2.3.2. Rhamnose conditional promoter and essentiality assessment 
 The vector pSCrhaB2-e-GFP (Cardona et al., 2006) was conjugated into K. pneumoniae 
kp52.145 WT. The exconjugants were selected in LB supplemented with trimethoprim. Ten 
colonies were picked and each grown overnight at 37ºC in M9 medium supplemented with 0.5%, 
0.2% of rhamnose or 0.5% of glucose. Next day, the bacterial suspensions were deposited in 
slides covered with thin layer of 0.8% (w/v) agarose and observed by light and fluorescent 
microscopy. The images were acquired using Axioscope 10 (Carl Zeiss) microscope coupled to 
a camera AxioCam MRm (Zeiss) and an endow GFP bandpass emission filter set with the 470 ± 
25 nm emission range, 525 ± 25 nm excitation. Images were digitally processed using ZEN 2012 
(Blue Edition) Service Pack 1 image software. 
 The rhamnose conditional promoter construct was performed as previously described 
(Ortega et al., 2007) by cloning a 306 bp fragment (Q-775 and Q-904) spanning from the 5’ region 
of bcnK into pSC200, giving rise to pDG10. The resulting vector possesses a rhamnose-inducible 
PrhaB upstream of the multiple cloning site, enabling to drive the expression of bcnK in the 
presence of rhamnose and repressing it in glucose. The vector’s conjugation was performed in 
LB supplemented with 0.5% rhamnose and selected in LB with 0.5% rhamnose and trimethoprim. 
The conditional mutants were grown overnight at 37ºC in M9 medium with 0.5% rhamnose, spun 
down and washed three times with PBS, resuspended in PBS and adjusted to an OD600 of 1 (Neat 
solution). Drops (10 µL) of Neat, 10-1, 10-2, 10-3 and 10-4 dilutions were plated in M9 agar square 
plates supplement with 0.5% (w/v) rhamnose or 0.5% (w/v) glucose and incubated at 37ºC. The 
strains XOA10 and XOA12 were used as a negative and positive control, respectively. 
 
2.4. Oxidative stress studies 
2.4.1. Transcriptional fusions to luxCDABE and luminescence assays 
Promoter region of bcnK, was amplified by PCR (Q-909 and Q-910). The amplicon with 
≈900 bp was digested and cloned into the digested and dephosphorylated pGSVTp-lux suicide 
vector and transformed into E. coli GT115. The primers for oxyR and waaE (Q-841 and Q-842; 
Q-852 and Q-853, respectively) were designed after ELIC method (Koskela & Frey, 2015) 
containing ≈25 bp homologous with the vector’s region adjacent to region where it will be cloned 
in pGSVTp-lux. The amplicons and digested vector were quantified in NanoVue Plus™ 
Spectrophotometer, mixed in a ratio of 3:1, respectively, in a final volume of 10 µL of Mili-Q water 
and incubated for 1 h at room temperature and transformed into E. coli GT115. The transformants 
colonies were selected in LB with trimethoprim, grown overnight and checked for luminescence 
on POLARstar® Omega for 12 h at 37ºC treated with and without paraquat 1.5 µM final 
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concentration. From the colonies that displayed luminescence, three of each construct were 
chosen and the vector was extract and transformed into E. coli β2163 and conjugated into K. 
pneumoniae and selected in LB with trimethoprim. The obtained exconjugants were checked for 
luminescence, grown overnight and luminescence and OD600 were measured in the 
presence/absence of serial dilution of paraquat (10; 5; 2.5 and 0 µM) for 12 h at 37ºC on 
POLARstar® Omega. The expression levels of each gene of interest in the different strains 
background were calculated as Relative Luminescence Units per OD600 (RLU/OD600) for each 
condition. 
 
2.5. B. cenocepacia BCN complementation and MIC assays 
B. cenocepacia ΔBcnAΔBcnB were complemented with pDG1 and pDA-CTHis through 
biparental conjugation and selected in LB with tetracycline giving rise to DNG4 and DNG5, 
respectively. B. cenocepacia ΔBcnAΔBcnB; DNG4 and DNG5 MIC’s were tested accordingly with 
(Wiegand et al., 2008). The strains were grown overnight in Mueller-Hinton cation adjusted, OD600 
adjusted to 0.005, inoculated in 100 well honeycomb plate with serial dilutions from 2048 µg/mL 
to 8 µg/mL of rifampicin. The plates were incubated for 24 h at 37ºC on Bioscreen C. Triplicates 
were performed for this assay. 
 
2.6. BcnK genomic studies 
The previously retrieved BcnK amino acid sequence from NCBI was used to perform the 
following BCN genomic studies. K. pneumoniae kp52.145 BcnK amino acid sequence was 
compared against Klebsiella genus (taxid: 570) using BLASTp and selecting non-redundant 
protein sequences search. Amino acids sequence alignment and phylogenetic data were 
generated by Clustal Omega v1.2.2 (Sievers et al., 2011). Neighbour-joining cladograms were 
generated from the alignment data using FigTree v1.4.2 software. The domain structure of BcnK 
was accessed on Conserved Domain Database (CDD) tool on NCBI. Neighbourhood gene 
studies were performed by SyntTax (Oberto, 2013). Interaction of BCNs (YceI’s) protein with other 
proteins and molecules was accessed using the Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING) (Szklarczyk et al., 2014). Amino acid sequence from B. cenocepacia 
CybB (GenkBank ID: CAR53635.1) was also retrieved from NCBI. 
 
2.7. Computational methods 
K. pneumoniae kp52.145 BcnK tridimensional (3D) folding prediction was generated in 
Protein Homology/analogy Recognition Engine V 2.0 (Phyre2) (Kelley et al., 2015) using amino 
acidic sequence and visualized in Jmol v13.0. BcnK molecular weight was predicted on ExPASy, 
Bioinformatics Resource Portal translation tool (Gasteiger et al., 2005). BcnK signal peptide 
prediction was performed on SignalP 4.1 Server in CBS website (Petersen et al., 2011). DNA 
sequence analysis and vectors figures were generated in SnapGene™ 1.1.3. Statistical analysis 
was performed with GraphPad Prim 6. 
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CHAPTER III – RESULTS AND DISCUSSION 
3.1. Activity of purified BcnK in an antibiotic protection assay  
BcnK was expressed in several vectors to obtain a pure functional protein for downstream 
assays. I first purified BcnK expressed in the pDA-CTHis vector (pDG1; Table S1) using Ni2+-
affinity chromatography followed by SDS-PAGE and Western-blot, which revealed a polypeptide 
band with a predicted molecular weight of 19.6 kDa (Figure 3.1). This protein was employed in 
an antibiotic protection assay using P. aeruginosa as a reporter strain. In the presence of BcnK, 
P. aeruginosa PAO1 showed increased resistance to PmB (approximately 65.5% increase in the 
%OD600) (Figure 3.2A). Although protection was an expected results, this assay was performed 
A                B 
Figure 3.1 – Verification of BcnK presence expressed from pDG1 during several steps of -Ni2+ chromatography 
purification procedure (A) SDS-PAGE of the soluble and membrane protein fractions; purification column flow through; 
washes with imidazole and elution of BcnK bound to the column, performed with the respective and concentrations 
of imidazole and the respective dialysis in PBS; (B) Western-Blot performed on crucial steps of BcnK purification. 
Figure 3.2 – In vitro protection assay of P. aeruginosa against PmB with 1.5 µM of BcnK. (A) BcnK expressed from  pDG1 (n=3; 
from an individual assay); (B) BcnK expressed from pDG8 (n=9; from 3 independent assays). Results correspond to the end points 
of 24 hours incubation shown in % OD600 relative to untreated control. Significant differences (* P<0.0001) were tested using 2way 
ANOVA. 
A             B 
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only once, as this protein rapidly formed aggregates during the purification and dialysis in PBS 
that precluded repeating the assay for statistical analysis. 
The rapid aggregation of purified BcnK made difficult to verify the actual amount of protein 
in the protection assay. BcnK aggregation may result from the lipid moiety N-acyl-S-sn-1,2-
diacylcerylcysteine present in BcnK N-terminus (Bishop, 2000), which is hydrophobic and enables 
BCNs to anchor in the bacterial membrane. Thus, dialyzing the purified protein in a polar solvent, 
such as PBS, likely resulted in aggregation. The same behavior was observed when BCNs 
orthologues from B. cenocepacia were purified from constructs containing the respective signal 
peptides (El-Halfawy & Valvano, 2013). To solve such obstacle, B. cenocepacia BCN orthologues 
were purified from constructs devoid of their signal peptides. The same approach was adopted 
here; bcnK gene was amplified without its predicted signal peptide (Figure S1) and cloned into 
the same backbone as pDG1, giving rise to pDG5. However, this construct resulted in reduced 
protein quantities after purification. To increase the protein expression in E. coli, two additional 
constructs containing bcnK without its signal peptide were cloned, giving rise to pDG7 (containing 
N- and C- terminus His-Tag) and pDG8 (containing a N-terminus His-Tag), were created using 
the IPTG inducible pET28a (+) vector. These constructs afforded sufficient quantities of protein 
expression for the purification based on SDS-PAGE and Western-blot of crude bacterial lysates 
(data not shown). However, protein obtained from pDG7 expression still aggregated, while that 
from pDG8 remained stable upon dialysis in PBS. The different solubility observed between these 
two recombinant proteins could depend on the His-tag’s (Woestenenk et al., 2004). While pDG7 
encodes BcnK with two His-tag’s, (one on N- and the other C-terminal), pDG8 encodes a protein 
with only one His-tag at the N-terminus. Yet, no detectable protection in P. aeruginosa protection 
assay was found with the pDG8 construct (Figure 3.2B). From the comparison of the results with 
the full-length mature and lapidated protein expressed from pDG1, we hypothesized that the His-
tag position in the recombinant protein could have an effect on its activity. In pDG1, BcnK has a 
C-terminus His-tag, while in pDG8 BcnK is expressed with an N-terminal his-tag, which may 
interfere with antibiotic binding. A new construct expressing a protein with a C-terminal His-tag 
was then created (pDG11). However, no BcnK protein could be found by SDS-PAGE of the crude 
lysates (data not shown). Analysis of the pDG11 DNA sequence indicated that a putative 
ribosomal binding site (Shine-Dalgarno, SD) sequence was too closely positioned to the start 
codon of bcnK (3 nucleotides upstream). The SD is responsible for the ribosome binding to the 
transcribed mRNA and typically should be positioned at 7-11 nucleotides of the translation start 
site (Chen et al., 1994). Because in pDG11 there is an upstream encoding region, lacZα, which 
possesses a SD sequence within 7 nucleotides from its start codon, we attempted to correct the 
reading frame by site-directed mutagenesis to create a LacZα-BcnK fusion that would be correctly 
expressed (Figure S2). Unfortunately, several colonies containing the putative translation-
corrected bcnK chimeric gene failed to express the protein, verified by SDS-PAGE analysis. 
We then hypothesized that the absence BcnK of activity in the protection assay could be 
related to BcnK misfolding. The expression of BcnK without signal peptide targets the BcnK 
protein into the cytosol, instead of the periplasmic space, where BcnK is predicted to locate 
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originally. The presence of the recombinant protein in the cytosol may result in protein misfolding 
(Dyson et al., 2004; Luan et al., 2004; Braun et al., 2002) This would explain the both lack of 
expression, as misfolded proteins are generally subjected to degradation by proteolysis (Kopito, 
2000; Baker & Sauer, 2006; Tomoyasu et al., 2001) and production of protein in a misfolded 
conformation may prevents antibiotic binding. Other possible explanation for the lack of 
expression is the formation of insoluble inclusion bodies (IBs), which is often observed when 
foreign genes are overexpressed in E. coli (Tsumoto et al., 2003; Lemercier et al., 2003). These 
IBs can be separated from the cell lysate by low speed centrifugation (2000 x g) (Hancock, 2001). 
However, we could not detect IBs in our lysates. Therefore, in future subsequent experiments, 
we propose to overcome the lack of expression by using pRF130 (Flannagan et al., 2007). This 
vector provides a cleavable signal peptide, which would help direct unlipidated, mature BcnK to 
the periplasmic space, where the protein should fold normally. 
In conclusion, although we initially observe BcnK protection of P. aeruginosa against 
PmB, this result could not be repeated with other constructs likely due to problems with protein 
expression and misfolding.  
 
3.2. The K. pneumoniae bcnK gene seems to be essential for bacterial viability 
To investigate the role of BcnK in K. pneumoniae antibiotic phenotype resistance we 
attempted to construct an unmarked bcnK gene deletion. For this purpose, I constructed the 
mutagenesis plasmid pDG4, which was employed for deletion mutagenesis as described in 
Material and Methods. However, no mutants were obtained after repeated attempts. In all cases, 
screening of the colonies though cPCR indicated only merodiploids (Figure 3.3). 
Therefore, we attempted to obtain a polar 
mutation in bcnK using pDG9. The rationale of this 
approach was to amplify an internal fragment of the 
bcnK coding region, which was cloned into the suicide 
pGPΩTp vector (Flannagan et al., 2007). The 
integration by homologous recombination of the 
resulting plasmid (pDG9) in the bcnK gene would 
result in a strong polar mutation due to the presence 
of the Ω-fragments in the vector that interrupt 
transcription in both directions (Flannagan et al., 
2007). Again no mutants were obtained through this 
method. 
Failure to obtain gene deletion or a polar 
mutation of bcnK suggested the possibility that this 
gene is essential for the viability of K. pneumoniae. 
Other BCN genes have been proposed to be 
essential in Salmonella enterica serovar Typhimurium 
(Knuth et al., 2004) and in Vibrio cholerae (Cameron 
Figure 3.3 – cPCR performed of K. pneumoniae 
trimethoprim sensitive colonies obtained after the 
second conjugation of bcnK of unmarked deletion 
using pDG2. K. pneumoniae merodiploid colonies 1 
and 2 were compared against K. pneumoniae WT 
purified chromosome and the purified knockout 
plasmid pDG2.  
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et al., 2008). In contrast BCNs orthologues in B. cenocepacia (El-Halfawy & Valvano, 2013), 
Neisseria meningitis (Donnarumma et al., 2015) and E. coli (Gerdes et al., 2003) are not essential. 
To verify the essentiality of bcnK in K. pneumoniae, we employed a strategy based on 
placing a rhamnose inducible promoter upstream of the chromosomal copy of the bcnK gene. 
First, we had to demonstrate that this conditional promoter works in K. pneumoniae. To test it, 
pSCrhaB2-e-GFP was conjugated into K. pneumoniae. This vector encodes a rhamnose-
inducible gene encoding the green fluorescent protein (GFP). GFP expression by this vector is 
suppressed in the presence of glucose. Figure 3.4 shows the different levels of fluorescence in 
K. pneumoniae expressing eGFP encoded from the vector pSCrhaB2-e-GFP. No visual 
differences are observed between bacteria growing in 0.2% and 0.5% rhamnose, showing that 
the rhamnose promoter is highly active irrespective of these rhamnose concentrations. However, 
fluorescent bacterial cells were not observed in cultures grown with glucose, indicating that the 
rhamnose promoter is inactive as expected and also observed in B. cenocepacia (Cardona et al., 
2006). Based on this information, we constructed pDG10, a derivative of pSCrhaB2-e-GFP where 
the GFP gene was replaced by bcnK. This plasmid was mobilized into the K. pneumoniae strain 
and the resulting recombinants, putatively containing a bcnK gene under the control of the 
rhamnose inducible promoter, were screened in M9 medium supplemented with glucose or 
rhamnose. However, all the colonies investigated could grow in both media (Figure 3.5), 
suggesting that bcnK is either not essential for K. pneumoniae viability or a very low level of 
constitutive expression in the absence of rhamnose is sufficient to overcome loss of viability. 
Future experiments will involve attempting to construct an unmarked deletion of bcnK in 
the presence of a complementing plasmid, with an exogenous BCN (that differs in nucleotide 
sequence with bcnK), and submitting the complemented bacteria to the unmarked deletion 
mutagenesis method. This method aims to show that, from complemented K. pneumoniae, bcnK 
can be deleted. If so, the further removal of the complementation plasmid from the defective 
mutants should demonstrate if bcnK is indeed essential for K. pneumoniae viability. 
Figure 3.4 – Microscopy of K. pneumoniae exconjugants expressing eGFP under the rhamnose inducible 
promoter. Bacteria were grown at the indicated concentrations of rhamnose and glucose. 
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3.3. bcnK regulation under various stress conditions 
This study also involved determining the regulation of bcnK under oxidative stress. 
Previously, El-Halfawy & Valvano (unpublished) demonstrated, using luciferase reporter 
plasmids, that B. cenocepacia BcnA expression is upregulated by oxidative stress. Many 
antibiotics induce oxidative stress when bacteria are exposed to sublethal concentrations (Albesa 
et al., 2004). If BcnK protein plays a role in antibiotic resistance, one could predict that it is also 
upregulated under the same conditions. We then applied the same luciferase method, as the one 
used for B. cenocepacia, by cloning the promoter regions of bcnK, upstream of a luxCDABE 
cluster present in the suicide vector pGSVTp-lux. 
To evaluate bcnK expression levels under oxidative stress, we constructed 
PbcnK::luxCDABE and PoxyR::luxCDABE. The latter construct was used as a positive control for 
oxidative stress since oxyR responds to oxidative stress (Honma et al., 2009; Loprasert et al., 2002; 
Seib et al., 2007). As a negative control, we constructed PwaaE::luxCDABE. The waaE gene 
encodes a protein needed for the inner-core lipopolysaccharide in K. pneumoniae 889 (Izquierdo 
et al., 2002), and is not stimulated by oxidative stress. Expression was examined by determining 
luminescence arising from the expression of the lux operon (Winson et al., 1998). 
These assays are still under way, but preliminary results obtained from stimulation with 
paraquat (a compound that elicits superoxide stress) in bacteria containing PbcnK::luxCDABE and 
PoxyR::luxCDABE suggest that bcnK is upregulated (data not shown), as it was previously reported 
for bcnA (El-Halfawy & Valvano, unpublised). Further studies will include antibiotics such as 
rifampicin, norfloxacin and ceftazidime which are known to induce oxidative stress in the bacteria. 
Figure 3.5 – K. pneumoniae bcnK essentiality assessment using the obtained exconjugants containing rhamnose 
inducible promoters (DNG9-11). K. pneumoniae wild type was complemented with pSCrhaB2 (kp52.145/pSCrhaB2) 
using rhamnose inducible promoter as control. XOA12 and XOA10 were used as rhamnose-dependent and rhamnose-
independent control mutant (Ortega et al., 2007). Bacteria were grown on the indicated rhamnose and glucose 
concentrations. 
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3.4. B. cenocepacia BCN complementation 
A B. cenocepacia ΔbcnA mutant shows increased susceptibility to PmB, rifampicin and 
norfloxacin (El-Halfawy & Valvano, 2013). Previous studies showed that BCNs from P. 
aeruginosa, Mycobacterium tuberculosis and S. aureus, could complement this mutant, indicating 
that these proteins have the same function as BcnA in conferring antibiotic resistance (El-Halfawy 
& Valvano, unpublished). In our study, the vectors pDG1, which encodes a full-length BcnK 
protein, was conjugated into B. cenocepacia 
ΔBcnAΔBcnB, resulting in strains DNG4 and 
DNG5, respectively. These complemented 
mutants were assessed for MIC against 
rifampicin, as it was done for BCNs from other 
species. The results (Table 3.1) showed 
increased MIC for complemented strains 
relative to non-complemented. However, this 
increased MIC values did not differ between 
pDG1 and the plasmid vector control. El-
Halfawy & Valvano (unpublished) used a 
different vector, pSCRhaB2, to complement 
the B. cenocepacia mutant. Such vector will be 
used in future complementation assays to 
clone bcnK, under the same conditions as in B. 
cenocepacia study. 
  
3.5. BCN in silico structural and genomic characterization of BCNs 
3.5.1. BcnA vs BcnK secondary structure comparison 
BCNs are a family of proteins with a β-barrel shape followed by an α-helix. BcnK 3D 
structure was modeled with the Phyre2 webtool. Figure 3.6 shows a prediction of the conserved 
secondary structure of the BCNs protein family, modelled with 100.0% confidence and 77.0% of 
amino acid sequence coverage. 
Potential BCN active amino acids were searched with the CDD webtool. However, no 
active residues were registered on this database. El-Halfawy & Valvano (unpublished) generated 
a BcnA/norfloxacin docking model. They showed that aspartic acid 82 (Asp) and Asp93, when 
replaced by alanine (a small nonpolar amino acid), resulted in reduced BcnA antibiotic binding 
activity. Using the same model, BcnA and BcnK were aligned by Clustal Omega (Figure 3.7) in 
an attempt to identify putative amino acids responsible for antibiotic binding. The amino acid 
alignment revealed that valine 107 (Val107) and glutamic acid 118 (Glu118) in BcnK correspond 
to BcnA’s Asp82 and Asp93, respectively. 3D predictions in Phyre2 showed that both amino acids 
assume the same position on the protein structure. Despite the differences, Asp and Glu residues 
are both polar and negatively charged amino acids. However, Val is a hydrophobic residue. This 
suggests that other residues on the rim, or slightly inside of the β-barrel, may also play a role in 
Rifampicin MIC 
Concentration 
(µg/mL) 
Strains 
WT OME4 pDG1 pDA-CTHis 
512 - - - - 
256 - - - - 
128 + - + + 
64 + + + + 
32 + + + + 
16 + + + + 
8 + + + + 
0 + + + + 
Table 3.1 – Rifampicin MIC determination of non-
complemented B. cenocepacia (WT); non-
complemented B. cenocepacia ΔbcnAΔbcnB (OME4); B. 
cenocepacia ΔbcnAΔbcnB complementation with bcnK 
(pDG1) and B. cenocepacia ΔbcnAΔbcnB 
complemented with pDG1 backbone (pDA-CTHis). 
Results expressed in growth (+) and no growth    (-) (n=9, 
3 independent experiments). 
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antibiotic binding. However, the 3D predictions may not be completely accurate, as the homology 
detection algorithm to build 3D models with the Phyre2 webtool (Kelley et al., 2015), may generate 
false positives even with proteins that are confidently aligned (Marks et al., 2012). 
Due to time constrains the role of identified amino acids could not be tested in this study. 
Nonetheless, these observations may guide future studies to identify key residues in BcnK by 
performing alanine site-replacement mutagenesis on the identified residues. Alanine consists on 
a small mass non-charged amino acid which rarely compromises the protein tertiary structure. 
Also, to identify other important residues, BcnK/antibiotic docking models would be performed. 
The resulting mutated protein would be used for antibiotic protection and fluorometric Nile Red 
binding assays. 
Figure 3.6 – 3D prediction of BcnK (left) and BcnA (right) visualized in Jmol. In red, are shown the corresponding residues 
for BcnK’s Val107 and BcnA’s Asp82 and in blue the corresponding BcnK’s Glu118 and BcnA’s Asp93. 
Val107 
Asp93 
Asp82 
Glu118 
BcnA BcnK 
V            E 
D            D 
            : 
 
Figure 3.7 – BcnK and BcnA amino acid sequence alignment obtained from Clustal Omega. In blue is BcnK’s residue, 
Val107, corresponding to BcnA’s Asp82 and in red is BcnK’s residue, Glu118, corresponding to BcnA’s Asp93. The 
following symbols stand for (*) identical residues; (:) identical charge; (.) identical property (hydrophobic or hydrophilic). 
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3.5.2. Klebsiella spp. BcnK genomic comparison 
 To compare BcnKs from Klebsiella species, BLASTp analyses were performed using all 
available Klebsiella (taxid: 570) genomic sequences. Clustal Omega was used to align the 
BLASTp hits (Table S5) and a cladogram was generated by FigTree (Figure S3). 
BLASTp revealed proteins with amino acid sequence homologies that varied between 
99% and 81% among 100 homologous identified sequences in Klebsiella species. The maximum 
difference of identities between homologous consisted of 24 residues. The cladogram shows that 
Klebsiella BCNs can be divided into 3 clusters. Due the lack of knowledge of the active residues 
of this protein family, we could not clarify if the observed difference in the residues among 
Klebsiella homologs plays a role in antibiotic binding activity. However, these alignments provide 
a tool for further studies of protein structure, prediction of antibiotic binding activity, functionality 
and evolutionary studies. 
 
3.5.3. bcnK neighborhood studies 
A neighboring gene comparison was done to evaluate and compare the BCNs 
conservation in K. pneumoniae genome and other species using SyntTax with BcnK as query. 
Figure S4 shows that the bcnK position is highly conserved on several K. pneumoniae strains. 
Also, in K. pneumoniae genomes, bcnK is isolated from other genes, ≈ 700 bp both upstream and 
downstream with no coding regions. The analysis for the ESKAPE isolates showed that BCNs 
genes are highly conserved in each bacterial species (Data not shown). No synteny was found 
for B. cenocepacia and E. feacium. However, yceJ or cybB, which encodes for a putative 
cytochrome b561 homologue was found associated to BCN genes from several species, such as 
P. aeruginosa, B. cenocepacia, E. coli and some Enterobacter species. In contrast, these genes 
were not associated to BCNs in K. pneumoniae, A. baumannii and S. aureus (Table 3.2). It is also 
important to notice that no synteny and BCNs homologous (searched by BLASTp) was found in 
E. faecium. The implications of these findings is discussed below (see section 3.8).  
 
3.8. A general hypothesis for BCNs cellular function 
BCN antibiotic binding activity has been studied in the Valvano’s lab. Recent unpublished 
data (Naguib & Valvano) show that BcnA’s antibiotic binding capacity is outcompeted by vitamin 
E, which binds more strongly to BcnA then antibiotics, thus displacing the antibiotics from the 
protein and increasing their freedom to exert inhibition of bacterial growth. 
 Structural studies in Thermus thermophilus (Handa et al., 2005) suggests that BCNs may 
play an important role in isoprenoid quinone (IQ) metabolism and/or transport and/or storage, as 
these proteins were isolated with polyisoprenoid side chain buried inside BCNs β-barrel. These 
side chains, which vary in length depending on the species (Collins & Jones, 1981), are 
precursors of IQ (Søballe & Poole, 1999). IQ consists on essential components electron-transport 
chain (ETC). IQ is found in membranes of both prokaryotes and eukaryotes, acting as electron 
and proton shuttles between complexes I or II to complex III on ETC pathway (Nowicka & Kruk, 
2010) (Figure 3.8). It is important to mention that enzymes other than complex I, II or III can 
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oxidize or reduce IQ, therefore ETC can be branched (Rasmusson et al., 2008). Overall, ETC is 
responsible for adenosine triphosphate (ATP) production under both aerobic and anaerobic 
conditions, depending on the final electron acceptor, creating a flow of electrons, thus generating 
proton motive force (Figure 3.8). Also, ETC represents an important mechanism for oxidative 
stress and gene regulation. Here, it will be focused the role of ETC on oxidative stress control. 
Reactive oxygen species (ROS) are toxic 
byproducts of aerobic metabolism and also they 
are formed due to environmental stress (Cabiscol 
et al., 2010). ROS are subsequently scavenged by 
several mechanisms of which IQ, known for its 
antioxidant activity (Do et al., 1996), is an example. 
Søballe et al., (1999) Lagendijk et al., (1996) 
suggest that IQ antioxidant properties are 
dependent on its high concentrations and its 
reduced ratio, protecting against lipid peroxidation, 
DNA oxidation from free ROS and modification of 
membrane proteins (Ernster & Dallaner, 1995). 
Condensing this information with the function 
suggested by Handa et al., (2005) and BCN 
upregulation under oxidative stress (El-Halfawy & 
Valvano, unpublished), it is now suggested that 
BCN may function by providing polyisoprenoid 
chains to the IQ pool, thus decreasing the cell 
sensibility to oxidative stress. 
The synteny study here shows an association in many species of cybB and BCN. This 
former gene encodes a putative cytochrome b561, a membrane protein with distinct molecular 
organization and spectral properties from other b-type cytochromes (Murakami et al., 1986). Its 
eukaryotic orthologous are functionality well described (Tsubaki et al., 2005; Lu et al., 2014), 
intervening on iron absorption (Glanfield et al., 2010) and in the glutathione-ascorbate cycle (Perin 
et al., 1988; Bérczi & Zimányi, 2014), regenerating vitamin E, which is responsible for processing 
ROS, by transferring electrons across the membrane from vitamin C (Lu et al., 2014). However, 
its functionality in prokaryote organisms remains unclear (Murakami et al., 1986). El-Halfawy & 
Valvano (unpublished) have shown that cybB is up-regulated by oxidative stress conditions. 
Purified CybB from E. coli is reduced by respiration substrates as a component of ETC, 
suggesting that these proteins intervene on ETC as electrons donors (Murakami et al., 1986). 
Further, the CybB redox potential was calculated as + 20 mV, depending on the cell physiological 
state, placing it before ubiquinones, a type of IQ (Kracke et al., 2015) in ETC. Together, these 
observations, coupled to the synteny data in this thesis, suggest that BCNs could play a significant 
role in ETC. 
Figure 3.8 – Example of electron transport chain 
during aerobic respiration from Paracoccus 
denitrificans, a model organism for respiration 
studies, (Mandigan et al., 2010). 
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This hypothesis predicts that bacteria not requiring oxygen for respiration would not have 
BCNs. This is supported by the observation in this thesis that E. faecium lacks BCN orthologs. E. 
faecium is strict fermenter and it lacks ETC, Kreb’s cycle and cytochromes (Willett, 1992). To 
strengthen our hypothesis that BCN and cybB might play a role on ETC and therefore be only 
present in organisms that are capable of aerobic respiration, we investigated other strict 
anaerobes. Streptococcus pyogenes (Gibson et al., 2000), Clostridium species and 
Acetobacterium woodii (Kracke et al., 2015), which lack ETC genes also lack BCN orthologs 
(Table 3.2). Together, the presence/absence of BCN and CybB supports the notion of these 
proteins being involved in ETC metabolism. Moreover, STRING database predictions suggest 
that these two genes are co-expressed, thus they might be expressed under the same 
physiological conditions, such as oxidative stress. In addition, microarray analyses suggest that 
BCN gene expression in E. coli is post-transcriptionally repressed by the FNR regulon 
overexpression (Durand & Storz, 2010). FNR consists on an oxygen sensor being active under 
anaerobic conditions. Its activation modulates the expression of a number of genes responsible 
for aerobic functions, repressing them and activating several genes encoding for anaerobic 
pathway (Salmon et al., 2003; Kang et al., 2005; Constantinidou et al., 2006) at transcriptional 
level, as well as post-transcriptional level through small RNAs (sRNA) by binding to mRNA and 
proteins (Waters & Storz, 2009). Also, studies made in Neisseria meningitis GNA1030 
(Donnarumma et al., 2015) showed that specific inhibitors of IQ redox action are applied to WT 
and Δgna1030 (N. meningitis BCNs) influence the survival of the bacteria, suggesting that BCNs 
intervene at some level on ETC. 
 
 
 
Species BCN CybB ETC cybB associated of BCN gene 
B. cenocepacia + + + + 
E. coli + + + + 
ESKAPE     
K. pneumoniae + + + - 
A. baumanni + + + - 
S. aureus + + + - 
E. faecium - - - NA 
P. aeruginosa + + + + 
Enterobacter species + + + Enterobacter spp. and E. cloacae 
Strict/aerotolerant anaerobes     
S. pyogenes - - - NA 
Clostridium species - - - NA 
A. woodii - - - NA 
Table 3.2 – Presence/absence of BCN and CybB in the genome of the indicated species based on BLASTp results. 
ETC presence/absence based on bibliography. cybB association with BCN gene obtained from synteny results. 
Among Enterobacter species only Enterobacter sp. and Enterobacter cloacae have cybB associated to BCN. NA = 
Not Applicable 
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Here, I suggest a model of BCNs cellular function, where these proteins are capable to 
hijack and/or storage and/or transport hydrophobic compounds, such as vitamin E and IQ, to 
CybB where these compounds are reduced by electrons from substrates of ETC and/or vitamin 
C (Figure 3.9). The resulting reduced compounds, such as IQ is then transported into the bacterial 
membrane entering on the ETC. This hypothesized pathway would be unnecessary or inactive 
under anaerobic conditions. 
 
 
4. Conclusions and perspectives 
Numerous attempts to purify a stable K. pneumoniae‘s BCN exhibiting antibiotic binding 
failed. This was probably due to BCN membrane lipid anchor that resulted in aggregation when 
dialyzed in PBS. Also, protein overexpression on the cytosol, in E. coli, resulted on misfolded 
BcnK. 
The construction of a K. pneumoniae BcnK defective mutants was attempted via 
unmarked deletion and insertion deletion methods. However, no mutants were obtained, thus 
bcnK essentiality was assessed by creating bcnK under the control of rhamnose inducible 
promoter. The bcnK rhamnose conditional mutants showed no lethal phenotype when grown in 
glucose, despite we showed that the rhamnose inducible promoter is functional in K. pneumoniae. 
Figure 3.9 – Schematic model of BCN cellular function. 1 – Extracellular BcnA or BcnK/BcnB on the periplasmic space can bind hydrophobic 
compounds such as quinones or vitamin E. 2 – BCNs deliver these compounds to cytochrome b561 (CybB). 3 – ETC substrates are 
oxidized on the cytosol by CybB that transports electron across the membrane reducing the compound present on BCNs. 4 – the reduced 
compound is transported in the periplasmic space acting as an antioxidant or 5 – Reduced isoprenoid quinones are transported into the 
inner membrane where they enter in the ETC or act as antioxidants. 
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This may be due to a low level of constitutive read-through transcription of bcnK, which would 
lead to a low level of protein expression that might be sufficient to overcome lethality. Alternatively, 
bcnK may not be an essential gene for K. pneumoniae, but this is not supported by the deletion 
and insertion mutagenesis results that consistently failed despite many repetitions. 
Preliminary results from oxidative stress assays suggest that bcnK is upregulated under 
oxidative stress conditions induced by paraquat. However, future assays using non-“regulated” 
gene by oxidative stress will be assessed as a negative control. 
B. cenocepacia defective on BCNs production was complemented with K. pneumoniae 
BCN and assessed for antibiotic MIC restoration. The MIC is indeed restored, however, it appears 
to be due to the used vector and not BcnK itself. Future assays will be addressed by cloning bcnK 
into the same vector as was used for B. cenocepacia studies. 
Structural modeling of BcnK in comparison to BcnA revealed two putative residues 
involved in antibiotic binding, Val107 and Glu118, which corresponded to BcnA Asp82 and Asp 
93, respectively. However, the hydrophobicity characteristics of Asp and Glu residues are 
different and it remains unknown how these residues participate in antibiotic binding. 
Nonetheless, this information could be useful for future protein antibiotic docking models and 
prediction of important restudies for site directed mutagenesis. 
Klebsiella spp. BCNs genomic comparisons indicated that these proteins are highly 
conserved despite they can be separated into three main clusters. 
BCNs synteny and BLASTp studies showed that BCNs are associated with cybB and in 
some bacteria, while both genes are absent in all examined strict anaerobes. This information 
allows us to suggest a model of BCNs cellular function whereby BCN acts to capture or 
transporter hydrophobic compounds that will be reduced by CybB, thus contributing to antioxidant 
activities of bacteria under aerobic conditions. 
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CHAPTER V – APPENDIXES 
5.1 – SUPPLEMENTARY TABLES 
 
 
 
 
 
 
 
 
 
Strain or Plasmid Description Source/reference 
Strains   
Escherichia coli   
    DH5α F- φ80dlacZΔM15 (ΔlacZYA-argF)U169 endA1 recA1 hsdR17(rK
- mK
+) supE44 deoR 
thi-1 nupG ΔgyrA96 relA1, λ- 
Lab stock 
    GT115 F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 rspL(StrA) endA1 ∆dcm 
uidA(∆MluI)::pir-116 ∆sbcC-sbcD 
InvivoGen 
    BL21 F- dcm ompT hsdS (rB
- mB
-) gal Novagen 
    β2163 F- RP4-2-Tc::Mu ΔdapA::(erm-pir) [KmR EmR] Institute Pasteur  
Klebsiella pneumoniae   
    kp52.145 Clinical isolate (serotype O1:K2) Nassif et al. (1989) 
    DNG1 kp52.145; PoxyR::luxCDABE; Tp
R This study 
    DNG6 kp52.145; PbcnK::luxCDABE; Tp
R This study 
    DNG15 kp52.145; PwaaE::luxCDABE; Tp
R This study 
DNG9 kp52.145; Prha::bcnK; Tp
R This study 
DNG10 kp52.145; Prha::bcnK; Tp
R This study 
DNG11 kp52.145; Prha::bcnK; Tp
R This study 
DNG12 kp52.145; PrhaB2-e-GFP This study 
Pseudomonas aeruginosa   
    PAO1 Non-CF clinical isolate Holloway (1955) 
Burkholderia cenocepacia   
    K56-2 ET12 clone related to J2315, clinical isolate BCRRC 
    XOA10 K56-2; Prha::BCAL1928; Tp
R Ortega et al. (2007) 
    XOA12 K56-2; Prha::arnB; Tp
R Ortega et al. (2007) 
    OME4 K56-2; ΔBcnAΔBcnB El-Halfawy & Valvano 
(2013) 
    DNG4 OME4; pDG1; TetR This study 
    DNG5 OME4; pDA-CTHis; TetR This study 
Vectors   
    pDA-CTHis oripBBR1, mob
+ Pdhfr, C-terminal His-tag, Tet
R D. Aubert, unpublished 
    pGPI-SecI-2 oriR6K ΩTp
R mob+, including an I-SceI restriction site; TpR  Flannagan et al. (2008) 
    pGPI-SecI-SacB oripBBR1 Tet
R mob+, expressing I-SceI, SacB; TetR Hamad et al. (2010) 
    pGSVTp-lux oriR6K Tp
R luxCDABE, derivate from pGSV3-Lux by replacing GmR for TpR cassette Bernier et al. (2008) 
    pGEM®-T Easy orif1 lacZ; Amp
R Promega 
    pET28a(+) ITPG inducible plasmid, KmR Novagen 
    pSCRhaB2-e-GFP oripBBR1 rhaR rhaS PrhaB mob
+; TpR Cardona et al. (2005) 
    pGPΩTp oriR6K ΩTp
R cassete mob+; TpR Flannagan et al. (2007) 
    pSC200 oriR6K rhaR rhaS PrhaB mob
+; TpR Ortega et al. (2007) 
    pUC19 oripMBI, lacZα; Amp
R Invitrogen 
    pRF130 oripBBR1, PrhaB, mob
+; TpR Flannagan et al. (2007) 
    pDG1 pDA-CTHis, bcnK, C-terminus His-tag, TetR This Study 
    pDG5 pDA-CTHis, bcnK without signal peptide, C-terminus His-tag, TetR This Study 
    pDG7 pET28a(+), bcnK without signal peptide, N- and C-terminus His-tag, KmR This Study 
    pDG8 pET28a(+), bcnK without signal peptide, N-terminus His-tag, KmR This Study 
    pDG11 pUC19, bcnK without signal peptide, C-terminal His-tag, AmpR This study 
    pDG2 pGPI-SceI-2 containing fragments (≈1000 bp) flanking bcnk; TpR This Study 
    pDG4 pGPI-SceI-2 containing fragments (≈300 bp) flanking bcnK; TpR This Study 
    pDG9 pGPΩTp, 297 bp internal fragment from bcnK; TpR This Study 
    pDG10 pSC200, 306 bp upstream region from bcnK; TpR This Study 
    pDG3 pGSVTp-lux PoxyR::luxCDABE Tp
R This Study 
    pDG6 pGSVTp-lux PwaaE::luxCDABE Tp
R This Study 
    pDG12 pGSVTp-lux PbcnK::luxCDABE; Tp
R This Study 
Table S1 – Strains, mutants and vectors used or created in this study. The following abbreviations 
stands for the respective antibiotic resistance: TpR: trimethoprim; TetR: tetracycline; AmpR: 
ampicillin; KmR: kanamycin; EmR: erythromycin. 
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Purpose Primer 
no. 
Oligonucleotide sequence, 5’-3’ Restriction 
site 
Gene cloning Q775 GGGCCCCATATGATGTTTTCAATAAGCCCTGTA NdeI 
 Q776 GGGCCCTCTAGATTTTGCATAGGCTTCCGTG XbaI 
 Q873 GGGTTTCATATGGCGGCTAAGGAATACAGTCTTG NdeI 
 Q880 GGGCCCCTCGAGTTTTGCATAGGCTTCCGTG XhoI 
 Q895 GGGCCCCTCGAGTTATTTTGCATAGGCTTCCGTG XhoI 
 Q841 AAATAGCTCATACACCCAAACAGTAGAATTCGGCCTACAACAAAGACATGC EcoRI 
 Q842 GGCGGCACTTGTGATTAAGAGTCAGAATTCTATTCATCCTCCATCGCCAC EcoRI 
 Q852 GGCCGCACTTGTGTATAAGAGTCAGAATTCACTATTTATCCGTTCTCTGTTTTGGCGGGC EcoRI 
 Q853 AAATAGCTCATACACCCAAACAGTAGAATTCCGGCACCTATGTGTACGAAAAGCGCC EcoRI 
 Q961 TTCCTTAGCCGCCATTGGATCCTCTAGAGTC - 
 Q962 GACTCTAGAGGATCCAATGGCGGCTAAGGAA - 
K. pneumoniae Q786 CCCTTTTCTAGATAATTTCGTTGCGTAAACTT XbaI 
Mutagenesis Q787 CCCAAACTCGAGGTACAGAAAGCAATGCGGTT XhoI 
 Q788 CCCGGCTCGAGCGTTCAGACTTTAAGCTTGATAA XhoI 
 Q789 TTTGGGAATTCGAACCGACCGATCCTGACC EcoRI 
 Q810 CAACTCTTACACGATGAAGG - 
 Q811 TCTAGAAAACATTTGTTATTCCCTTTC XbaI 
 Q812 TCTAGAGCCTATGCAAAATAAGTAAA XbaI 
 Q813 GAATGACCAGCCAGTTCACC - 
 Q902 GGGCCCTCTAGACCGCATTGCTTTCTGTACTTGCC XbaI 
 Q903 GGGCCCGAATTCGTTGGGAAACGTTTTAAC EcoRI 
 Q904 GGGCCCTCTAGAGGTTTTCACTGGCAGCGTGA XbaI 
    
Species Strain Type Accession Number Description Entry Date 
K. pneumoniae kp52.145 Nucleotide FO834906.1 Full genome sequence 09/08/2015 
K. pneumoniae kp52.146 Protein CDO15049.1 YceI 09/08/2015 
B. cenocepacia J2315 Protein CAR53634.1 BCAL3311 09/08/2015 
B. cenocepacia J2316 Protein CAR53635.1 BCAL3312 02/08/2016 
Table S2 – Primes generated for this study and respective restriction enzymes. Underlined bases 
represent the restriction site. Bases in bold represents the homology region with pGSVTp-lux vector  
Table S3 – List of genomic and protein sequences obtained from NCBI used in this thesis with 
information referring species, strain, type of sequence (nucleotide or protein), accession number, 
description of the sequence and entry date. 
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Equilibration buffer 
Final concentration Volume 
20 mM Na2HPO4 20 mL of 0.1 M 
500 mM NaCl 10 mL of 5 M 
10 mM Imidazole 1 mL of 1 M 
Milli-Q water 69 mL 
Lysis buffer (10 mL) 
Final concentration Volume 
20 mM Na2HPO4 2 mL of 0.1 M 
500 mM NaCl 1 mL of 5 M 
10 mM MgCl2 0.2 mL of 0.5 M 
DNAse 50 µg/mL 0.5 mg 
Protease Inhibitor 1x 1 mL 10x 
10 mM Imidazole 100 µl of 1M 
10% Glycerol 1 mL 
0.2% Triton X-100 20 µL 
Milli-Q Water 4.68 mL 
Purification buffers 
Final concentration 
50 mM Imidazole 75 mM Imidazole 400 mM imidazole 
Washing buffer Washing Buffer Elution Buffer 
20 mM Na2HPO4 10 mL of 0.1 M 10 mL of 0.1 M 3 mL of 0.1 M 
1.5 mM NaCl 15 mL of 5 M - - 
150 mM NaCl - 1.5 mL of 5 M 450 µL of 5 M 
Protease Inhibitor 1X - - 1.5 mL of 10x 
10 mM Imidazole 2.5 mL of 1 M 3.75 mL of 1 M 6 mL of 1 M 
Milli-Q Water 22.5 mL 34.75 mL 4.05 mL 
Final volume 50 mL 50 mL 15 mL 
Table S4 – Composition of the solution used for protein purification protocols. (A) Lysis buffer; 
(B) Equilibration buffer; (C) Washing and elution buffers used for BcnK purification. 
A            B 
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Species Strain Accession Number Entry Date Cluster 
Kp kp52.145 CDO15049.1 02/08/2016 1 
Kp BWH 46 KDH45308.1 02/08/2016 1 
Kp B5055 WP_016528802.1 02/08/2016 1 
Kp IS43 CDL09552.1 02/08/2016 1 
Kp; Ko MULTISPECIES (510 results) WP_004148751.1 02/08/2016 1 
Kp; Ko MULTISPECIES (47 results) ESM52217.1 02/08/2016 1 
Kp k1773 SAV78042.1 02/08/2016 1 
Kp MULTISTRAINS (13 results) WP_021313024.1 02/08/2016 1 
Kp BIDMC 36 ESL39202.1 02/08/2016 1 
Kp UCI76 KMI59035.1 02/08/2016 1 
Kp k263 SAT12336.1 02/08/2016 1 
Kp MGH 66 KDL58125.1 02/08/2016 1 
Kp W2-1-ERG2 SBY54108.1 02/08/2016 1 
Kp MS 92-3 EGF61318.1 02/08/2016 1 
Kp k2334 SAV41132.1 02/08/2016 1 
Kp UHKPC81 EOY77384.1 02/08/2016 1 
Kp UCI 26 EWD54348.1 02/08/2016 1 
Kp BIDMC 25 ESL49963.1 02/08/2016 1 
Kp ATCC 13884 EEW41939.1 02/08/2016 1 
Kp BIDMC 47 EWE15600.1 02/08/2016 1 
Kp UCI70 KMI53420.1 02/08/2016 1 
Kp k2290 SBI21147.1 02/08/2016 1 
Kp NTUH-K2044 BAH63914.1 02/08/2016 1 
Kp k722 SAX24660.1 02/08/2016 1 
Kp UCI94 KMI90325.1 02/08/2016 1 
Kp 98_KPNE WP_049204778.1 02/08/2016 1 
Kp MULTISTRAINS (206 results) WP_004151852.1 02/08/2016 1 
Kp MULTISTRAINS (35 results) WP_004891166.1 02/08/2016 1 
Kp k1773 WP_064152600.1 02/08/2016 1 
Kp 6234 KHQ25135.1 02/08/2016 1 
Kp k1781 SAY06168.1 02/08/2016 1 
Kp k1319 SAW93657.1 02/08/2016 1 
Kp SB3193 CDQ55550.1 02/08/2016 1 
Kp CHS162 KMD23806.1 02/08/2016 1 
Kp F1-9-ERG1 SBZ89122.1 02/08/2016 1 
Kp CHS136 KMX50881.1 02/08/2016 1 
Kp k414 SAT33337.1 02/08/2016 1 
Table S5 – List of bacterial strains possessing a BCNs homologous obtained from BLASTp results, 
deploying BcnK as query and used to construct the cladogram from Figure S3. The species code, 
strains, accession number and entry date are associated with the attributed cluster (1, 2 or 3). 
Similar protein sequences are grouped in MULTISPECIES (more than one species) or 
MULTISTRAINS (more than one strain). Klebsiella pneumoniae (Kp), Klebsiella oxytoca (Ko), 
Klebsiella variicola (Kv), Klebsiella quasipneumoniae (Kqp). 
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Kp MGH116 KMH67375.1 02/08/2016 1 
Kp SKLX2993 WP_040225745.1 02/08/2016 1 
Kp KP-11U WP_032412495.1 02/08/2016 1 
Kp MULTISTRAINS (40 results) WP_004898943.1 02/08/2016 1 
Kp k263 WP_064161572.1 02/08/2016 1 
Kp KP-1 WP_032628321.1 02/08/2016 1 
Kp ST323:941530379 WP_040148358.1 02/08/2016 1 
Kp SKLX2891 WP_065890525.1 02/08/2016 1 
Kp SB3432 WP_020947796.1 02/08/2016 1 
Kp 50531633 WP_032429905.1 02/08/2016 1 
Kp MULTISTRAINS (4 results) WP_032438274.1 02/08/2016 1 
Kp MULTISTRAINS (2 results) WP_032415997.1 02/08/2016 1 
Kp MULTISTRAINS (2 results) WP_064172264.1 02/08/2016 1 
Kp MULTISTRAINS (4 results) WP_032420194.1 02/08/2016 1 
Kp k2290 WP_064146264.1 02/08/2016 1 
Kp DHQP1002001 WP_068814988.1 02/08/2016 1 
Kp yzusk-4 AKG99567.1 02/08/2016 1 
Kp UCI70 WP_048333775.1 02/08/2016 1 
Kp k722 WP_064181430.1 02/08/2016 1 
Kp 5422 WP_031593102.1 02/08/2016 1 
Kp MULTISTRAINS (3 results) WP_016831241.1 02/08/2016 1 
Kp CCGT01000026 WP_040188956.1 02/08/2016 1 
Kp 359_ECLO WP_048969219.1 02/08/2016 1 
Kp F1-9-ERG1 WP_065808059.1 02/08/2016 1 
Kp CHS162 WP_048290620.1 02/08/2016 1 
Kp CHS136 WP_050885681.1 02/08/2016 1 
Kp 570_KPNE WP_048987887.1 02/08/2016 1 
Kp MULTISTRAINS (3 results) WP_046623832.1 02/08/2016 1 
Kp MSULTISTRAINS (6 results) WP_038431357.1 02/08/2016 1 
Kp KLP28 KTG51533.1 02/08/2016 1 
Kp K57-33 WP_060528076.1 02/08/2016 1 
Kp CFSAN044574 WP_069345197.1 02/08/2016 1 
Kp; Kv MULTISPECIES (19 results) WP_008804418.1 02/08/2016 2 
Kp YH43 WP_061154214.1 02/08/2016 2 
Kqp 21_GR_13 WP_065881285.1 02/08/2016 3 
Kp MULTISTRAINS (4 results) WP_023297838.1 02/08/2016 2 
Kp; Kqp; Kv MULTISPECIES (21 results) WP_004203155.1 02/08/2016 3 
Kp MGH 80 WP_032735938.1 02/08/2016 2 
Kp 50878013 WP_060619667.1 02/08/2016 2 
Kp 837_KPNE WP_049010347.1 02/08/2016 2 
Kp MGH92 WP_048330424.1 02/08/2016 2 
Kp; Kv MULTISPECIES (12 results) WP_016161315.1 02/08/2016 2 
Kp; Kv MULTISPECIES (2 results) WP_064323602.1 02/08/2016 2 
Kv 801 WP_043875107.1 02/08/2016 2 
Kv At-22 WP_012967822.1 02/08/2016 2 
Kp k2254 WP_064154439.1 02/08/2016 3 
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Kqp KPSB59 WP_032453272.1 02/08/2016 3 
Kqp 07A044 WP_032456269.1 02/08/2016 3 
Kqp FI_HV_2014 WP_050533298.1 02/08/2016 3 
Kqp 385_ECLO WP_049116548.1 02/08/2016 3 
Kp 12 3578 WP_017900775.1 02/08/2016 3 
Kp Multistrains (3 results) WP_023318555.1 02/08/2016 3 
Kp UCICRE 14 WP_032428892.1 02/08/2016 3 
Kqp 865_KPNE WP_049013562.1 02/08/2016 3 
Kqp KQQSB11 WP_044523846.1 02/08/2016 3 
Kp k2254 SAU45131.1 02/08/2016 3 
Kqp 01A030 CDQ14977.1 02/08/2016 3 
Kp k1457 SAX28671.1 02/08/2016 3 
Kqp 18A069 CDN00725.1 02/08/2016 3 
Kp W2-15-ERG14 SCA20417.1 02/08/2016 3 
Kp MGH96 KMH14419.1 02/08/2016 3 
Kp UCICRE 14 ESL74126.1 02/08/2016 3 
Kp MGH113 KMH48341.1 02/08/2016 3 
MFSISPVFFWANIYVPADFEDYCVNTLKKTALLSVLALYIPVSQAAAKEYSLDPQHTSVVISWNHFGFSNPTAYISDVSG
KLAFDKENPEKSSVNVTLPVKTIDAHVKALTDEFLGKEYFDVKTFPNATFQSTKVESKGDNKYDVEGNLTIKGITKPVVLH
AVLNKQDMHPMVKKEAIGFDATGVIKRSDFKLDKYVSAVSDNVTITLSTEAYAK 
Figure S1 – BcnK amino acid sequence displaying its putative signal peptide (green), predicted 
to be cleaved between Alanine45 and Alanine46 (SQA-AA). 
Figure S2 – Constructed vector pDG11 showing lacZα gene fragment and N-region of bcnK 
coding region with the respective primers for point mutation assays. The primers display the 
adenine to be added aiming to fuse both genes. 
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Figure S3 – Cladogram of Klebsiella 
genus amino acidic comparison. K. 
pneumoniae kp52.145 BcnK is shown in 
red letters on Cluster 1. BCNs are 
separated in three main cluster 1 (Blue), 
2 (Red) and 3 (Green). Cladogram 
constructed using Clustal Omega v1.2.2 
and FigTree v1.4.2. The code of each 
sequence in displayed on Table S5.  
0.01 
CLUSTER 1 
CLUSTER 3 
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Figure S4 – SyntTax report obtain for 
BcnK. At the center, in blue and bold, 
stands bcnK, each arrow represents 
conserved a gene with an associated 
color. Genes with no synteny are 
presented in white genes.   
